<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2803245127
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LONSURF
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TRIFLURIDINE,TIPIRACIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15,6.14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1944.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAIHO PHARMACEUTICAL CO LTD ( KITAJIMA PLANT )" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAIHO PHARMACEUTICAL CO LTD ( KITAJIMA PLANT )
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LES LABORATORIES SERVIER 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC59 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lonsurf is a type of cancer chemotherapy which belongs to the group of medicines called &quot;cytostatic antimetabolite medicines&quot;.</p><p>&nbsp;</p><p>Lonsurf contains two different active substances: trifluridine and tipiracil.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Trifluridine stops the growth of cancer cells.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Tipiracil stops the trifluridine from being broken down by the body, helping trifluridine to work longer.</p><p>&nbsp;</p><p>Lonsurf is used to treat adults with colon or rectal cancer - sometimes called &lsquo;colorectal&rsquo; cancer and stomach cancer (including cancer of the junction between the oesophagus and the stomach).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; It is used when the cancer has spread to other parts of the body (metastases).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; It is used when other treatments have not worked - or when other treatments are not suitable for you.</p><p><u>Lonsurf may be given in combination with bevacizumab. It is important that you also read the package leaflet of bevacizumab. If you have any questions about this medicine, ask your doctor.</u>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lonsurf </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to trifluridine or tipiracil or any of the other ingredients of this medicine (listed in section 6).</p><p>Do not take Lonsurf if the above applies to you. If you are not sure, talk to your doctor or health care provider before taking Lonsurf.</p><p>&nbsp;</p><p><strong>b. &nbsp;</strong><strong>Take special care with Lonsurf</strong></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, health care provider or pharmacist before taking Lonsurf if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you have liver problems</p><p>If you are not sure, talk to your doctor, health care provider or pharmacist before taking Lonsurf.</p><p><strong>&nbsp;</strong></p><p>Treatment may lead to the following side effects (see section 4):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;a reduced number of certain types of white blood cells (neutropenia) which are important for protecting the body against bacterial or fungal infections. As a consequence of neutropenia, fever (febrile neutropenia) and blood infection (septic shock) may occur</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a reduced number of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a reduced number of platelets in the blood (thrombocytopenia) which are important to stop bleeding and work by clumping and clotting blood vessel injuries</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal problems.</p><p><strong>Tests and checks</strong></p><p>Your doctor or health care provider will do blood tests before each cycle of Lonsurf. You start a new cycle every 4 weeks. The tests are needed because Lonsurf can sometimes affect your blood cells.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>This medicine is not indicated for use in children and adolescents below the age of 18 years. This is because it may not work or be safe.</p><p><strong>c.&nbsp;&nbsp; Taking other medicines, herbal or dietary supplements </strong></p><p>Tell your doctor, health care provider or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. This is because Lonsurf can affect the way some other medicines work. Also some other medicines can affect the way Lonsurf works.</p><p>In particular tell your doctor, health care provider or pharmacist if you are taking medicines used for treatment of HIV, such as zidovudine. This is because zidovudine may not work as well if you are taking Lonsurf. Talk to your doctor or health care provider about whether to switch to a different HIV medicine.</p><p>If the above applies to you (or you are not sure), talk to your doctor, health care provider or pharmacist before taking Lonsurf.</p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp; Pregnancy, breast-feeding and contraception</strong></p><p>If you are pregnant or breast-feeding or if you think you might be pregnant or are planning to have a baby, ask your doctor, health care provider or pharmacist for advice before taking this medicine. Lonsurf may harm your unborn baby.</p><p>&nbsp;</p><p>Pregnancy</p><p>If you become pregnant, you and your doctor or health care provider will have to decide if the benefits of Lonsurf are greater than the risk of harm to the baby.</p><p>&nbsp;</p><p>Breast-feeding</p><p>Do not breast-feed if you are taking Lonsurf as it is not known whether Lonsurf passes into the mother&rsquo;s milk.</p><p>&nbsp;</p><p>Contraception</p><p>You must not become pregnant while taking this medicine. This is because it may harm your unborn baby.</p><p>You and your partner should use effective methods of contraception while taking this medicine. You should also do this for 6 months after you stop taking the medicine. If you or your partner becomes pregnant during this time, you must talk to your doctor, health care provider or pharmacist straight away.</p><p>&nbsp;</p><p><strong><u>Fertility</u></strong>&nbsp;</p><p><u>Lonsurf may affect your ability to have a baby. Talk to your doctor for advice before using it.</u>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>e.&nbsp;&nbsp; Driving and using machines</strong></p><p>It is not known whether Lonsurf changes your ability to drive or use machines. Do not drive or use any tools or machines if you experience symptoms that affect your ability to concentrate and react.</p><p>&nbsp;</p><p><strong>f. Important information about some of the ingredients of</strong><strong> Lonsurf</strong></p><p>Lonsurf contains lactose</p><p>If you have been told by your doctor or health care provider that you have an intolerance to some sugars, contact your doctor or health care provider before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor, health care provider or pharmacist has told you. Check with your doctor, health care provider or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>How much to take</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor or health care provider will decide the right dose for you - the dose depends on your weight and height and if you have kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Lonsurf comes in two strengths. Your doctor may prescribe both strengths for your prescribed dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor or health care provider will tell you how many tablets to take each time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will take a dose 2 times a day.</p><p>&nbsp;</p><p><strong>When to take Lonsurf</strong></p><p>You will take Lonsurf for 10 days during the first 2 weeks, and then have 2 weeks off. This 4-week period is called a &lsquo;cycle.&rsquo; The specific dosing schedule is as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Week 1 </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take the dose 2 times a day for 5 days</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; then have 2 days off - no medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Week 2</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take the dose 2 times a day for 5 days</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; then have 2 days off - no medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Week 3</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Week 4</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No medicine</p><p>You will then start again with another cycle of 4 weeks following the above pattern.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>How to take</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LONSURF&nbsp;should be prescribed by physicians experienced in the administration of anticancer therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LONSURF&nbsp;is a cytotoxic drug. Need caution when handling LONSURF to minimize risk of exposure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personal not taking LONSURF&nbsp;should not be exposed to it.</p><ul><li>Take this medicine by mouth.</li><li>Tablets should be swallowed as a whole with a glass of water.</li><li>The tablets should not be broken or crushed.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take within 1 hour after your morning and evening meals.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands after handling this medicine.</p><p>&nbsp;</p><p><strong>a. If you take more Lonsurf than you should</strong></p><p>If you take more Lonsurf than you should, talk to a doctor or health care provider or go to a hospital straight away. Take your pack(s) of medicine with you.</p><p>&nbsp;</p><p><strong>b. If you forget to take Lonsurf</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you forget a dose, talk to your doctor, health care provider or pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, health care provider or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects may happen with this medicine <u>when it is taken alone or in combination with bevacizumab</u>:</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>Tell your doctor or health care provider immediately</strong> if you notice any of the following serious side effects (many of the side effects are shown in laboratory tests - for example those affecting your blood cells):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia (<em>very common</em>), febrile neutropenia (<em>common</em>) and septic shock (rare<em>uncommon</em>). The signs include chills, fever, sweating or other sign of bacterial or fungal infection (see section 2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia <em>(very common). </em>The signs include feeling short of breath, tiredness or looking pale (see section 2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (<em>very common</em>) and diarrhoea (<em>very common</em>), which may lead to a dehydration if severe or persistent.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe gastrointestinal problems: abdominal pain <em>(common)</em>, ascites <em>(rareuncommon)</em>, colitis <em>(rareuncommon)</em>, acute pancreatitis <em>(uncommon), </em>ileus <em>(uncommon)</em> and subileus <em>(uncommon)</em>. The signs include intense stomach or abdominal pain that can be associated with vomiting, blocked or partly blocked bowel, fever or swelling of the abdomen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia (<em>very common</em>). The signs include unusual bruising or bleeding (see section&nbsp;2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary embolism <em>(uncommon)</em>: blood clots in lungs. The signs include shortness of breath and pain in the chest or in the legs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial lung disease has been reported in patients receiving the medicine. The signs include difficulty in breathing, shortness of breath, with cough or fever.</p><p>Some of these serious side effects may lead to death.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Tell your doctor or health care provider if you notice any of the following side effects. Many of the side effects are shown in laboratory tests - for example those affecting your blood cells. Your doctor or health care provider will be looking out for these side effects in your test results.</p><p>&nbsp;</p><p><strong>Very common: may affect more than 1 in 10 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced white blood cells called leucocytes - can increase your risk for infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of mucous membranes in mouth&nbsp;</p><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling generally out of sorts (malaise)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of albumin in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased bilirubin in your blood - can cause yellowing of skin or eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced number of white blood cells called lymphocytes - can increase your risk for infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in your hands or legs or feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness, swelling, pain on the palms of your hands and soles of your feet (hand-foot syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of numbness or pins and needles in hands or feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth pain or problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of mucous membranes - this could be inside the nose, mouth, throat, eyes, vagina, lungs or gut</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased liver enzymes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; protein in your urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, itchy or dry skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling short of breath, airway or lungs, chest infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>viral infection</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>pain in your joints</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>feeling dizzy, headache&nbsp;</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>high blood pressure</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>mouth ulcers</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>muscle pain</u>&nbsp;</p><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low or high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots, e.g. in the brain or legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test results indicating problems with clotting making you bleed more easily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; more noticeable heart-beat, chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal increase or decrease in heart rate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in your heart trace (ECG - electrocardiogram)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased number of white blood cells called monocytes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased lactate dehydrogenase level in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of phosphates, sodium, potassium &nbsp;or calcium in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced white blood cells called granulocytes or monocytes - can increase your risk for infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar (hyperglycaemia), increased salt, urea, creatinine and potassium in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test result indicating inflammation (C-Reactive Protein increased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ear pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of spinning (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy, headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny or bloody nose, sinus problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat, hoarse voice, problems with your voice</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness, itching of the eye, eye infections, watery eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision troubles as blurred vision, double vision, decreased vision, cataracts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating, passing gas, indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or inflammation in upper or lower part of digestive tract</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation, swelling or bleeding in your bowel</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation and infection in your gut</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation or increased acid in your stomach or gullet, reflux</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful tongue, polyps inside your mouth, mouth ulcers, retching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bad breath, tooth decay, tooth or gum problems, bleeding gums, gum infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or pain in your joints or big toes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or discomfort in your arms or legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, including pain from the cancer&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone pain, muscle pain, muscle weakness or spasms, pain in tendons, nerves or ligaments</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of being cold</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shingles (pain and vesicular rash on skin over nerve tracts affected by nerve inflammation from herpes zoster virus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation or infection of bile ducts, increase in the diameter of the bile duct</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough, infection of the sinuses, throat infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation or infection in your bladder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in urine test, blood in urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems passing water (urine retention), loss of bladder control (incontinence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; athlete&rsquo;s foot - fungal infection of feet, yeast infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accumulation of fluid in the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in the menstrual cycle</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting (syncope)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burning sensation, unpleasant, increased or loss of sense of touch and other non-severe neurological troubles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised itchy rash, red skin, blisters, skin sloughing off, hives, acne</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating more than normal, sensitivity to light, nail problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problem with sleeping or falling asleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of total protein in the blood feeling of numbness or pins and needles in hands or feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness, swelling, pain on the palms of your hands and soles of your feet (hand-foot syndrome)</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Rare: may affect up to 1 in 1 000 people</u></strong>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>inflammation and infection in your gut</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>athlete&rsquo;s foot - fungal infection of feet, yeast infections</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>reduced white blood cells called granulocytes - can increase your risk for infection</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>swelling or pain in your big toes</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>swelling in your joints</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>increased salt in your blood</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>burning sensation, unpleasant, increased or loss of sense of touch</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>fainting (syncope)</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>vision troubles as blurred vision, double vision, decreased vision, cataracts</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>dry eyes</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>ear pain</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>inflammation in upper part of digestive tract</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>pain in upper or lower part of digestive tract</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>accumulation of fluid in the lungs</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>bad breath, gum problems, bleeding gums</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>polyps inside your mouth</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>inflammation or bleeding in your bowel&nbsp;</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>increase in the diameter of the bile duct</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>raised red skin, blisters, skin sloughing off</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>sensitivity to light</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>inflammation in your bladder&nbsp;</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>changes in urine test</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>blood clots, e.g. in the brain or legs</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>changes in your heart trace (ECG - electrocardiogram)</u>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>low level of total protein in the blood</u>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of side effects</u></strong></p><p>If you experience any side effects, talk to your doctor, health care provider or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. &bull; LONSURF is a cytotoxic drug; need caution when handling to minimize risk of exposure. &bull; The tablets should not be divided, broken or crushed. &bull; Transport and store medicine in the original container or blister. &bull; For medication administration, use gloves and wash hands thoroughly before and after. If gloves are not worn, tip tablets and from their container/blister pack directly into a disposable medicine cup. &bull; People who are not taking patient should not be exposed to it. &bull; Caution should be observed in handling broken or crushed tablets Avoid direct contact of the LONSURF with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable. &bull; Pregnant should avoid exposure to LONSURF tablets. &bull; Family members use gloves when handling laundry or cleaning within or around toilets. &bull; Close the lid before flushing the toilet and flush twice after each use by patient, for 48 hours after receiving chemotherapy. If available, use separate bathroom from family members. &bull; Conduct double washing of linens and wash them separately from other family laundry. &bull; If your doctor tells you to stop taking the meditation, or expired. Do not throw away via wastewater or household waste. Ask your pharmacist how to throw away medicine you no longer use, or return it to your pharmacist, who will destroy them according to disposal of dangerous substance guidelines. &bull; These measures will help protect environment. &bull; Only keep the medicine if your doctor tells you to.<br />Do not use this medicine after the expiry date which is stated on the outer carton or blister tray after &ldquo;EXP.&rdquo; The expiry date refers to the last day of that month.<br />Storage conditions: store below 30&deg;C. Store in the original carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lonsurf 15/6.14mg film-coated tablet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are trifluridine and tipiracil. Each film-coated tablet contains 15 mg trifluridine and 6.14&nbsp;mg tipiracil</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core: lactose monohydrate, starch pregelatinised (maize) and stearic acid (see section 2 &ldquo;Lonsurf contains lactose&rdquo;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Film coat: hypromellose, macrogol (8000), titanium dioxide (E171), and magnesium stearate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Printing ink: shellac, iron oxide red (E172), iron oxide yellow (E172), titanium dioxide (E171), indigo carmine aluminium lake (E132), carnauba wax and talc.</p><p>&nbsp;</p><p>Lonsurf 20/8.19mg film-coated tablet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are trifluridine and tipiracil. Each film-coated tablet contains 20 mg trifluridine and 8.19&nbsp;mg tipiracil.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core: lactose monohydrate, starch pregelatinised (maize) and stearic acid (see section 2 &ldquo;Lonsurf contains lactose&rdquo;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Film coating: hypromellose, macrogol (8000), titanium dioxide (E171), iron oxide red (E172) &nbsp;and magnesium stearate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Printing ink: shellac, iron oxide red (E172), iron oxide yellow (E172), titanium dioxide (E171), indigo carmine aluminium lake (E132), carnauba wax and talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Lonsurf 15/6.14mg is a white, biconvex, round, film-coated tablet, printed with “15” on one side and “102” and “15 mg” on the other side in grey ink.

•	Lonsurf 20/8.19mg is a pale red, biconvex, round, film-coated tablet, printed with “20” on one side and “102” and “20 mg” on the other side in grey ink.

Each pack contains 20 film-coated tablets (2 blisters of 10 tablets each). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Les Laboratoires Servier</p><p>50 rue Carnot</p><p>92284 Suresnes Cedex</p><p>France</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer </strong></p><p>Les Laboratoires Servier Industrie &ndash; Gidy</p><p>905, route de Saran</p><p>45520 Gidy, France</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p>&nbsp;</p><p>Saudi Arabia<br />Servier Saudi Arabia Scientific Office<br />3533 Al Hawiy&nbsp;- Hitteen Dist.<br />1st floor - Office #101<br />Gulf Countries<br />Les Laboratoires Servier Scientific Office<br />P.O. Box 1586, Level 115, Arenco Tower, Dubai Media City<br />8<br />Kingdom of Saudi Arabia<br />Tel.: +966 011 252 2330<br />E-mail: regulatory.sa1@servier.com<br />Sheikh Zayed Road, Dubai, UAE<br />Tel: +971 4 3329903<br />E-mail: magdy.abdou@servier.com</p><table border="0" cellspacing="0" cellpadding="0" style="width:460.5pt"><tbody><tr><td style="vertical-align:top; width:230.2pt"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 07.2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;لونسيرف هو أحد أنواع العلاج الكيميائي للسرطان وهو ينتمي إلى مجموعة الأدوية التي تسمى &quot;الأدوية مضادة المستقلبات الموقفة للخلايا&quot;.</p><p dir="RTL">يحتوي &nbsp;لونسيرف على مادتين فعالتين مختلفين: ترايفلوريديين و تيبيراسيل.</p><p dir="RTL">&middot;&nbsp; ترايفلوريدين يوقف نمو الخلايا السرطانية</p><p dir="RTL">&middot;&nbsp; تيبيراسيل يوقف تفكك ترايفلوريدين في الجسم، مما يساعده على العمل لمدة أطول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستعمل &nbsp;لونسيرف لعلاج البالغين المصابين بسرطان القولون أو المستقيم &ndash; والذي يسمى أحيانا سرطان &rsquo;القولون والمستقيم&lsquo;. وسرطان المعدة (ويتضمن سرطان منطقة الاتصال بين المريء والمعدة).</p><p dir="RTL">&middot;&nbsp;&nbsp; يستعمل عندما يكون السرطان قد انتشر إلى أماكن أخرى في الجسم<strong> </strong>(الأورام النقيلة).</p><p dir="RTL">&middot;&nbsp;&nbsp; يستعمل عندما لا تعمل العلاجات الأخرى &ndash; أو عندما تكون العلاجات الأخرى غير مناسبة لك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكن التداوي بـ لونسيرف <strong>LONSURF</strong> بالتزامن مع بيفاسيزوماب <strong>bevacizumab</strong>. من الضروري أن تقرأ أيضا النشرة التي في عبوة بيفاسيزوماب <strong>bevacizumab</strong>. إذا ثار في ذهنك أي سؤال حول هذا الدواء، فاستشر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><!--[if !supportLists]--></p><p dir="RTL">&nbsp;</p><p dir="RTL">أ&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول &nbsp;لونسيرف :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ترايفلوريدين أو تيبيراسيل أو تجاه أي من مكونات هذا الدواء الأخرى (المذكورة في القسم ٦).</p><p dir="RTL">لا تتناول &nbsp;لونسيرف إذا كان ما ورد أعلاه ينطبق عليك. إذا لم تكن متأكدا، تحدث إلى طبيبك أو مزوّد الرعاية الصحية قبل أن تتناول &nbsp;لونسيرف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب توجيه عناية خاصة مع &nbsp;لونسيرف </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك، مزوّد الرعاية الصحية أو الصيدلاني قبل تناول &nbsp;لونسيرف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات كلوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات كبدية</p><p dir="RTL">إذا كان لديك شك، تحدث إلى طبيبك، مزوّد الرعاية الصحية أو الصيدلاني قبل تناول &nbsp;لونسيرف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب العلاج إلى حدوث التأثيرات الجانبية التالية (راجع القسم ٤)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناقص عدد أنواع معينة من خلايا الدم البيضاء (نقص العَدِلات) الهامة لحماية الجسم ضد حالات العدوى البكتيرية أو</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفطرية. وكنتيجة لنقص العدلات، من الممكن أن تحدث الحمى (نقص العدلات الحموي) وعدوى الدم (صدمة إنتانية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناقص عدد خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناقص عدد الصفيحات في الدم (قلة الصفيحات) الهامة لإيقاف النزف والتي تعمل عن طريق إغلاق وتخثير إصابات الأوعية</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات مَعِدِية مِعَوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاختبارات والفحوصات</strong></p><p dir="RTL">سيقوم طبيبك أو مزوّد الرعاية الصحية بإجراء اختبارات للدم قبل كل دورة علاجية من &nbsp;لونسيرف. ستبدأ دورة علاجية جديدة كل أربعة أسابيع. الاختبارات مطلوبة لأن &nbsp;لونسيرف قد يؤثر في بعض الأحيان على خلايا الدم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون </strong></p><p dir="RTL">لا يوصى باستعمال &nbsp;لونسيرف من أجل الأطفال والمراهقين الذين تقل أعمارهم عن ١٨ سنة. &nbsp;وهذا لأنه قد لا يعمل أو قد لا يكون آمنا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول الأدوية الأخرى، المكملات العشبية&nbsp; أو الغذائية</strong></p><p dir="RTL">أخبر طبيبك، مزوّد الرعاية الصحية أو الصيدلاني إذا كنت تتناول حاليا أو تناولت مؤخرا أو قد تتناول أي أدوية أخرى. هذا يشمل الأدوية التي يمكن الحصول عليها دون وصفة طبية والأدوية العشبية. وهذا عائد إلى أن &nbsp;لونسيرف يمكنه التأثير على الطريقة التي تعمل بعض الأدوية الأخرى بها. كما إن&nbsp; بعض الأدوية الأخرى قد تؤثر على طريقة عمل &nbsp;لونسيرف.</p><p dir="RTL">بشكل خاص، أخبر طبيبك، مزوّد الرعاية الصحية أو الصيدلاني إن كنت تتناول أدوية تستعمل لعلاج فيروس العوز المناعي البشري، مثل زيدوفودين. وهذا عائد إلى أن زيدوفودين قد لا يعمل بنفس الجودة إذا كنت تتناول &nbsp;لونسيرف. تحدث إلى طبيبك، مزوّد الرعاية الصحية عما إذا كان يجب التحوّل إلى دواء مختلف لعلاج فيروس العوز المناعي البشري.</p><p dir="RTL">إذا كان ما تقدم ينطبق عليك (أو إذا لم تكن متأكدا)، تحدث إلى طبيبك، مزوّد الرعاية الصحية أو الصيدلاني قبل تناول &nbsp;لونسيرف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">قد يؤثر لونسيرف LONSURF على قدرتك على الإنجاب; ويلزم طلب استشارة طبيبك قبل بدء التداوي به.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;الحمل، الإرضاع ومنع الحمل</strong></p><p dir="RTL">إذا كنت حاملا أو مرضعة، أو تعتقدين بأنك ربما كنت حاملا أو كنت تخططين للحمل، فاطلبي نصيحة طبيبك أو مزوّد الرعاية الصحية أو الصيدلاني قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;لونسيرف قد يسبب الأذى للطفل الذي لم يولد بعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل</p><p dir="RTL">إذا أصبحت حاملا، سيتعين عليك وعلى طبيبك أو مزوّد الرعاية الصحية اتخاذ القرار فيما إذا كانت الفوائد المرجوة من &nbsp;لونسيرف تفوق إمكانية إلحاق الأذى بالطفل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الإرضاع</p><p dir="RTL">امتنعي عن الإرضاع إذا كنت تتناولين &nbsp;لونسيرف &nbsp;لأنه من غير المعروف ما إذا كان &nbsp;لونسيرف ينتقل إلى حليب الأم.<br />&nbsp;</p><p dir="RTL">منع الحمل</p><p dir="RTL">يجب ألا تحملي أثناء تناول هذا الدواء. وهذا عائد إلى أنه قد يسبب الأذى لطفلك الذي لم يولد بعد.</p><p dir="RTL">يجب أن تستعملي أنت وشريكك وسائل فعالة لمنع الحمل أثناء تلقي هذا الدواء. ويجب أيضا أن تستمري بهذا لمدة ستة شهور بعد التوقف عن تناول الدواء. إذا أصبحت أنت أو شريكتك حاملا في هذه الفترة، فيجب أن تتحدثي / تتحدث إلى طبيبيك أو مزود الرعاية الصحية أو الصيدلاني على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;قيادة السيارات وتشغيل الآلات</p><p dir="RTL">ليس من المعروف ما إذا كان &nbsp;لونسيرف يؤثر على قدرتك على قيادة السيارة أو تشغيل الآليات. امتنع عن القيادة أو استعمال الأدوات أو الآليات إذا عانيت من أعراض تؤثر على قدرتك على التركيز والتفاعل.</p><p>&nbsp;</p><p dir="RTL">معلومات هامة تتعلق ببعض مكونات &nbsp;لونسيرف</p><p dir="RTL">&nbsp;يحتوي &nbsp;لونسيرف على اللاكتوز.</p><p dir="RTL">إذا كان طبيبك أو مزوّد الرعاية الصحية قد أخبرك أنك مصاب بعدم تحمّل أنواع معينة من السكر، فاتصل بطبيبك أو بمزوّد الرعاية الصحية قبل أن تتناول هذا الدواء.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دوما بالطريقة التي وصفها لك طبيبك، مزوّد الرعاية الصحية أو الصيدلاني. وفي حال الشك يجب إستشارة طبيبك،<br />مزوّد الرعاية الصحية أو الصيدلاني.<br />ما هي الكمية التي يجب أن تتناوله ا<br />&bull; سيقرر طبيبك الجرعة الصحيحة المناسبة لك تعتمد الجرعة على وزنك وطولك وما إذا كنت تعاني من مشاكل كلوية . &ndash;<br />&bull; يتوفر لونسيرف بتركيزين. قد يصف لك طبيبك كلا التركيزين من أجل جرعتك الموصوفة .<br />&bull; سيخبرك طبيبك أو مزوّد الرعاية الصحية ما هو عدد الأقراص التي تتناولها كل مرة .<br />&bull; ستتناول جرعتك مرتين يوميا.<br />متى تتناول لونسير ف<br />ستتناول لونسيرف لمدة ١٠ أيام أثناء الأسبوعين الأولين، ثم تتوقف عن تناوله لمدة أسبوعين. هذه الفترة التي تستمر ٤ أسابيع<br />تدعى &rsquo;دورة&lsquo;. برنامج الجرعات المحدد هو كما يلي :<br />&bull; الأسبوع ١<br />- تناول الجرعة مرتين يوم يا لمدة ٥ أيام<br />- ثم توقف عن تناول الدواء لمدة يومين لا دوا ء &ndash;<br />&bull; الأسبوع ٢<br />- تناول الجرعة مرتين يوميا لمدة ٥ أيام<br />- ثم توقف عن تناول الدواء لمدة يومين لا دوا ء &ndash;<br />&bull; الأسبوع ٣<br />- لا دوا ء<br />&bull; الأسبوع ٤<br />- لا دوا ء<br />بعد ذلك ستبدأ من جديد دورة علاجية أخرى لمدة ٤ أسابيع باتباع نفس ال نموذج المذكور أعلاه .<br />كيف تناول هذا الدوا ء<br />&bull; يجب أن يوصف لونسيرف من قبل طبيب مختصّ بإعطاء العلاجات المضادة للسرطان .<br />&bull; لونسيرف دواء سامّ للخلايا. يجب توخي الحذر عند التعامل مع لونسيرف لتقليل امكانية التعرّض له.<br />&bull; يجب عدم تعريض الأفراد الذين لا يتناولون لونسيرف إل يه<br />&bull; تناول هذا الدواء عن طريق الفم .<br />&bull; يجب ابتلاع الأقراص كاملة مع كأس من الماء .<br />&bull; يجب الامتناع عن كسر الأقراص أو سحقها .<br />&bull; تناوله في غضون ساعة واحدة بعد وجبة الصباح وبعد وجبة المساء .<br />&bull; اغسل يديك جيدا قبل وبعد التعامل مع الأقراص .<br />4<br />أ. إذا تناولت جرعة أكبر مما ينبغي من لونسيرف<br />إذا تناولت أكثر مما ينبغي من لونسيرف، تحدث إلى طبيبك أو مزوّد الرعاية الصحية أو توجّه إلى مستشفى على الفور. خذ معك علبة<br />)علب( الدواء .<br />ب. إذا نسيت تناول لونسيرف<br />&bull; إذا نسيت تناول إحدى الجرعات، تحدث إلى طبيبك أو مزوّد الرعاية الصحية أو الصيدلاني.<br />&bull; لا تتناول جرعة مضاعفة للتعويض عن الجرعة التي نسيت تناولها.<br />إذا كانت لديك أي أسئلة إضافية تتعلق باس تعمال هذا الدواء، فالرجاء طلب المزيد من المعلومات من طبيبك أو الصيدلاني.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب<em> </em>هذا الدواء تأثيرات جانبية، على الرغم من عدم حدوثها لدى كافة الأفراد. من الممكن أن تحدث التأثيرات الجانبية التالية عند تناول هذا الدواء سواء بمفرده أو بالتزامن مع بيفاسيزوماب bevacizumab:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثيرات جانبية خطيرة:</strong></p><p dir="RTL"><strong>أخبر </strong><strong>طبيبك أو مزوّد الرعاية الصحية على الفور</strong> إذا لاحظت حدوث أي من التأثيرات الجانبية الخطيرة التالية (تظهر العديد من التأثيرات الجانبية في الفحوص المخبرية &ndash; مثل تلك التي تؤثر على خلايا الدم لديك):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة العدلات (شائعة جدا)، قلة العدلات الحموية (شائعة) وصدمة إنتانية (نادرة). تشمل العلامات القشعريرة، الحمى، التعرّق أو علامات أخرى للعدوى البكتيرية أو الفطرية (راجع القسم ٢).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (شائع جدا). تشمل العلامات الشعور بضيق النفس، تعب أو الشحوب (راجع القسم ٢).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ (شائع جدا) والإسهال، مما قد يسبب الجفاف إذا كان شديدا ومستمرا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات معدِية مِعَوية شديدة: ألم في البطن (شائع)، استسقاء (نادر)، التهاب القولون (غير شائع)، التهاب البنكرياس الحاد (غير شائع)، علّوص (انسداد معوي) (غير شائع) وعلّوص جزئي (غير شائع). تشمل العلامات الألم الشديد في المعدة أو البطن الذي قد يترافق بالتقيؤ، انسداد الأمعاء أو انسدادها الجزئي، حمى أو تورّم البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الصفيحات في الدم (شائعة جدا). تشمل العلامات حدوث تكدّم أو نزف غير اعتيادي (راجع القسم ٢).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صمامة رئوية (غير شائعة): خثرات دموية في الرئتين. تشمل العلامات ضيق النفس وألم في الصدر أو في الساقين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذكر حدوث مرض الرئة الخلالي لدى المرضى الذين يتلقون الدواء في اليابان . تشمل علاماته صعوبة التنفس, ضيق التنفس, مع سعال أو حمى.</p><p dir="RTL">قد يؤدي بعض من هذه التأثيرات الجانبية الخطيرة إلى حدوث الوفاة. &nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية أخرى</strong><strong> </strong></p><p dir="RTL">أخبر طبيبك أو مزوّد الرعاية الصحية إذا لاحظت حدوث أي من التأثيرات الجانبية التالية. تظهر العديد من التأثيرات الجانبية في الفحوص المخبرية &ndash; مثل تلك التي تؤثر على خلايا الدم لديك. سيبحث طبيبك أو مزوّد الرعاية الصحية عن هذه التأثيرات الجانبية في نتائج الفحوص المخبرية الخاصة بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدا: قد تصيب أكثر من </strong><strong>(قد تصيب حتى ١ من كل ١٠ أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناقص الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب الشديد (الإنهاك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناقص عدد خلايا الدم البيضاء التي تدعى<em> </em>&nbsp;كريات الدم البيضاء &ndash; مما قد يزيد إمكانية الإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأغشية المخاطية في الفم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد تصيب حتى ١ من كل ١٠ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبدل الطعم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضعف عام (توعّك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدل منخفض من الألبومين في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدل البيليروبين في دمك &ndash; الذي قد يسبب اصفرار الجلد أو المنطقة البيضاء من العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تناقص عدد خلايا الدم البيضاء التي تدعى<em> </em>&nbsp;اللمفاويات &ndash; مما قد يزيد إمكانية الإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في يديك أو ساقيك أو قدميك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو اضطرابات في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الأغشية المخاطية &ndash; وقد يكون هذا داخل الأنف، الفم، الحلق، العينين، المهبل، الرئتين أو الجهاز الهضمي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدل الإنزيمات الكبدية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروتين في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح، جلد حاك أو جاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضيق النفس أو الممرات التنفسية أو الرئتين، عدوى صدرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفيروسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار والصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong><strong>:</strong><strong> قد تصيب حتى ١ من كل ١٠٠ شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم منخفض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خثرات دموية، مثل حدوثها في الدماغ أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج اختبارات دم تشير إلى وجود اضطرابات في التخثّر مما يجعلك تنزف بسهولة أكبر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالخفقان، ألم في الصدر &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض غير طبيعي في معدل ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع عدد خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع عدد خلايا الدم البيضاء اتي تدعى الوحيدات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدلات خميرة نازعة هيدروجين اللاكتيت في دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معدلات منخفضة من الفوسفات، الصوديوم، البوتاسيوم، أو الكالسيوم في دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناقص عدد خلايا الدم البيضاء التي تدعى الوحيدات - مما قد يزيد إمكانية الإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع معدل السكر (فرط السكر في الدم)، ارتفاع البولة، الكرياتينين والبوتاسيوم في دمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج اختبارات دم تشير إلى التهاب (ارتفاع معدل البروتين التفاعلي C)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوران (دوار)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف أو نزفه، اضطرابات في الجيوب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الحلق، بحّة الصوت، اضطرابات في الصوت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار، حكة في العين، عدوى العين، عيون دامعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ، خروج غازات، سوء الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في القسم السفلي من الجهاز الهضمي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم أو نزف في أمعائك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو عدوى في جهازك الهضمي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو ارتفاع معدل الحمض في معدتك أو مريئك، الرجع الحمضي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لسان مؤلم ، تجشؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسوس الأسنان، اضطرابات في الأسنان ، عدوى في اللثة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبيّغ (احمرار) الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ازعاج في الساعدين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم، بما في ذلك ألم بسبب السرطان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العظام، ألم أو تشنج في العضلات، ألم في الأوتار، الأعصاب أو الأربطة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالبرد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهربس النطاقي (ألم واندفاع حويصلي على الجلد على مسارات العصب المتأثرة بالتهاب العصب بسبب فيروس الهربس النطاقي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب كبدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أو عدوى في القنوات الصفراوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال، عدوى في الجيوب، أو في الحلق<em> </em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في المثانة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل عند التبول (احتباس البول)، فقد القدرة على التحكم بالمثانة (سلس البول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الدورة الشهرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشاكل العصبية غير الشديدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي حاك بارز ، شرى،&nbsp; عدّ (حب الشباب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرّق أكثر من الطبيعي ، مشاكل في الأظافر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في النوم أو النعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بتنميل أو الإحساس بوخز أو لسع في الأطراف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار أو تورم أو الشعور بالألم في راحتي اليد أو أخمص القدمين (متلازمة اليد والفم)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة: قد تصيب حتى شخص من بين 1000 شخص</strong></p><p dir="RTL"><em>&bull; </em>التهاب أو عدوى بالأمعاء</p><p dir="RTL"><em>&bull; </em>قدم الرياضي &ndash; عدوى فطرية في القدمين، حالات عدوى بالخميرة</p><p dir="RTL"><em>&bull; </em>انخفاض خلايا الدم البيضاء التي تسمى الخلايا الحبيبية أو المحبب ات - يمكن أن يزيد من خطر الإصابة بالعدوى</p><p dir="RTL"><em>&bull; </em>تورم أو ألم في أصبع القدم الكبير</p><p dir="RTL"><em>&bull; </em>تورم في المفاصل</p><p dir="RTL"><em>&bull; </em>زيادة نسبة الملح في الدم</p><p dir="RTL"><em>&bull; </em>الإحساس بحرقان على نحو مؤذ ، انخفاض الاحساس باللمس أو فقدانه بالكلية</p><p dir="RTL"><em>&bull; </em>الإغماء (فقدان الوعي<em>(</em></p><p dir="RTL"><em>&bull; </em>اضطرابات بصرية مثل تشوش الرؤية، ازدواج الرؤية، تناقص الرؤية، السادّ البصري</p><p dir="RTL"><em>&bull; </em>جفاف العينين</p><p dir="RTL"><em>&bull; </em>ألم في الأذن</p><p dir="RTL"><em>&bull; </em>تورم الجزء العلوي من القناة الهضمية</p><p dir="RTL"><em>&bull; </em>ألم في الجزء العلوي أو السفلي من القناة الهضمية</p><p dir="RTL"><em>&bull; </em>تراكم للسوائل في الرئتين</p><p dir="RTL"><em>&bull; </em>رائحة نفس كريهة، مشكلات في اللثة، نزف في اللثة</p><p dir="RTL"><em>&bull; </em>بوليبات داخل الفم</p><p dir="RTL"><em>&bull; </em>التهاب أو نزيف في الأمعاء</p><p dir="RTL"><em>&bull; </em>زيادة في قطر القناة الصفراوية</p><p dir="RTL"><em>&bull; </em>جلد أحمر مرتفع ، بثور ، تقشر الجلد</p><p dir="RTL"><em>&bull; </em>الحساسية للضوء</p><p dir="RTL"><em>&bull; </em>التهاب المثانة</p><p dir="RTL"><em>&bull; </em>تغيّر في تحليل البول</p><p dir="RTL"><em>&bull; </em>جلطات دموية، في الدماغ أو الساقين ؛ مثلا</p><p dir="RTL"><em>&bull; </em>تغيرات في مخطط كهربية القلب<em> (ECG)</em></p><p dir="RTL"><em>&bull;</em> معدّل منخفض من إجمالي البروتين في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">إذا أصبت بأي تأثيرات جانبية، تحدث إلى طبيبك، مزوّد الرعاية الصحية أو الصيدلاني. وهذا يشمل أي تأثيرات جانبية ممكنة الحدوث وإن لم يرد ذكرها في هذه النشرة. كما يمكنك أيضا الإبلاغ عن التأثيرات الجانبية مباشرة إلى نظام الإبلاغ الوطني. بإبلاغك عن التأثيرات الجانبية، يمكنك المساعدة بتوفير مزيد من المعلومات عن سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدا عن متناول أيدي الأطفال وعن مرأى عيونهم.<br />&bull; لونسيرف دواء سامّ للخلايا. يجب توخي الحذر عند التعامل مع لونسيرف لتقليل امكانية التعرّض له.<br />&bull; يجب عدم تقسيم الأقراص أو كسرها أو سحقها .<br />&bull; نقل الأقراص وحفظها يجب أن يكون في عبوتها أو حاوية الأقراص الأصلية .<br />&bull; من أجل إعطاء الأقر اص، استعمل القفازات واغسل يديك جيدا قبل وبعد إعطاء الأقراص. إذا لم تكن ترتدي القفازات،<br />أخرج الإقراص من الحاوية / العبوة إلى كوب أو كأس طبي نبوذ .<br />&bull; يجب عدم تعريض الأفراد الذين لا يتناولون الدواء إليه .<br />&bull; يجب توخي الحذر عند التعامل مع الأقراص المكسورة أو المسحوق ة<br />تجنّب التماس المباشر بين لونسيرف والجلد أو الأغشية المخاطية. إذا حدث هذا التلامس، فاغسل المنطقة جيدا بالماء<br />والصابون، واشطف العينين جيدا بماء معقم، أو بماء عادي إذا لم يتوفر الماء المعقم.<br />&bull; يجب تفادي تعريض الحوامل لأقراص لونسيرف .<br />&bull; يجب أن يستعمل أفراد الأسرة القفازات عند التعامل مع الملابس للغسيل أو عند تنظيف المرحاض أو ما حوله .<br />&bull; أغلق غطاء المرحاض قبل شطفه ويجب شطفه مرتين في كل مرة يستعمله فيها المر يض، لمدة ٤٨ ساعة بعد تلقي العلاج<br />الكيميائي. من المفضّل استعمال حمام منفصل عن حمام الأسرة إذا كان متوفرا.<br />&bull; يجب غسل ملاءات الأسرة مرتين ويجب غسلها بمعزل عن ملاءات وملابس بقية أفراد الأسرة .<br />&bull; إذا أشار عليك طبيبك بالتوقف عن تناول الدواء أو إذا انتهت مدة صلاحيته، فلا تتخلص منه في مياه الصرف الصحي أو مع<br />نفايات المنزل. اسأل الصيدلاني عن طريقة التخلّص من الأدوية التي لم تعد بحاجة إليها، أو أعده إلى الصيدلاني، فهو<br />سيتخلّص منها بالتماشي مع إرشادات التخلص من المواد الخطرة .<br />&bull; هذه الإجراءات تساعد على حماية البيئة.<br />&bull; يمكنك الاحتفاظ بالدواء فقط إذا أشار عليك الطبيب بذلك.<br />7<br />لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المبيّن على العلبة وعلى حاويات الأقراص بعد EXP .<br />تاريخ انتهاء الصلاحية هو آخر يوم من الشهر المشار إليه .<br />شروط الحفظ: احتفظ بها في درجة حرارة أقل من ٣٠ درجة مئوية. احتفظ بها في عبوتها الأصلية .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لونسيرف ١٥ ملغ / ٦٫١٤ ملغ أقراص ملبّسة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي ترايفلوريدين وتيبيراسيل. كل قرص ملبّس يحتوي على ١٥ملغ ترايفلوريدين و٦٫١٤ ملغ تيبيراسيل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; داخل القرص: لاكتوز أحادي الماء، نشاء مسبق التهليم (ذرة) وحمض الستياريك . (راجع القسم ٢ &quot;يحتوي&nbsp; لونسيرف <em>LONSURF</em> على اللاكتوز&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; غلاف القرص: هيبروميللوز، ماكروغول ( ٨٠٠٠)، &nbsp;ثاني أوكسيد التيتانيوم (E171)، وستيارات المغنيزيوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; حبر الطباعة: شيللاك، أكسيد الحديد الأحمر (E172)، أكسيد الحديد الأصفر (E172)، ثاني أوكسيد التيتانيوم (E171)، إنديغو كارمن ألمنيوم ليك (E132)، شمع الكارنوبا وتالك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لونسيرف ٢٠ ملغ /٨٫١٩ ملغ أقراص ملبّسة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي ترايفلوريدين وتيبيراسيل. كل قرص ملبّس يحتوي على ٢٠ ملغ ترايفلوريدين و٨٫١٩ ملغ تيبيراسيل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; داخل القرص: لاكتوز أحادي الماء، نشاء مسبق التهليم (ذرة) وحمض الستياريك (راجع القسم ٢ &quot;يحتوي&nbsp; لونسيرف <em>LONSURF</em> على اللاكتوز&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; غلاف القرص: هيبروميللوز، ماكروغول ( ٨٠٠٠)، &nbsp;ثاني أوكسيد التيتانيوم (E171)، أكسيد الحديد الأحمر (E172)، وستيارات المغنيزيوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; حبر الطباعة: شيللاك، أكسيد الحديد الأحمر (E172)، أكسيد الحديد الأصفر (E172)، ثاني أوكسيد التيتانيوم (E171)، إنديغو كارمن ألمنيوم ليك (E132)، شمع الكارنوبا وتالك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيف يبدو &nbsp;لونسيرف وما هي محتويات العبوة</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;لونسيرف ١٥ ملغ / ٦٫١٤ ملغ هي أقراص مستديرة بيضاء محدبة الوجهين ملبّسة، طبع &ldquo;15&rdquo; على أحد وجهيها و &ldquo;102&rdquo; و &ldquo;15 mg&rdquo; على الوجه الآخر بحبر رمادي اللون.</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;لونسيرف ٢٠ ملغ /٨٫١٩ ملغ هي أقراص مستديرة حمراء فاتحة محدبة الوجهين ملبّسة، طبع &ldquo;20&rdquo; على أحد وجهيها و &ldquo;102&rdquo; و &ldquo;20 mg&rdquo; على الوجه الآخر بحبر رمادي اللون.</p><p dir="RTL">تحتوي كل عبوة على ٢٠ قرصا ملبسا (شريطين بلاستيكيين يحتوي كل منهما على ١٠ أقراص) هناك عامل مجفّف ضمن كل رقاقة شريط بلاستيكي.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الجهة الحاملة لإجازة التسويق:</strong></p><p>مختبرات سيرفييه</p><p>Les Laboratoires Servier</p><p>50, rue Carnot</p><p>92284 Suresnes cedex</p><p>France</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>الجهة المصنعة</strong><strong>:</strong></p><p>&nbsp;Les Laboratoires Servier Industrie &ndash; Gidy</p><p>905, route de Saran</p><p>45520 Gidy,</p><p>France</p><p>&nbsp;</p><p>للحصول على أي معلومات تتعلق بهذا الدواء، الرجاء الاتصال بالوكيل المحلي للجهة الحاملة لإجازة التسويق.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:246.35pt"><p>المملكة العربية السعودية<br />المكتب العلمي سيرفييه العربية السعودي ة<br />٣٥٣٣ الحوي حطّين &ndash;<br />الطابق الأول المكتب # &ndash; ١٠١<br />المملكة العربية السعودية<br />هاتف: ٩٦٦٠١١٢٥٢٢٣٣٠ +<br />البريد الالكتروني: regulatory.sa1@servier.com<br />&nbsp;</p></td><td style="vertical-align:top; width:246.4pt"><p>بلدان الخليج<br />المكتب العلمي لمختبرات سيرفييه<br />ص.ب. ١٥٨٦ ، الطابق ١١٥ ، برج أرينكو، مدينة دبي<br />الإعلام ية<br />طريق الشيخ زايد، دبي، الإمارات العربية المتحدة<br />هاتف: ٩٧١٤٣٣٢٩٩٠٣ +<br />البريد الالكتروني: magdy.abdou@servier.com</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ آخر مراجعة لهذه النشرة: 07-2023.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lonsurf 15 mg/6.14 mg film-coated tablets
Lonsurf 20 mg/8.19 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lonsurf 15 mg/6.14 mg film-coated tablets
Each film-coated tablet contains 15 mg trifluridine and 6.14 mg tipiracil (as hydrochloride).

Excipient with known effect
Each film-coated tablet contains 90.735 mg of lactose monohydrate.

Lonsurf 20 mg/8.19 mg film-coated tablets
Each film-coated tablet contains 20 mg trifluridine and 8.19 mg tipiracil (as hydrochloride).

Excipient with known effect
Each film-coated tablet contains 120.980 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Lonsurf 15 mg/6.14 mg film-coated tablets
The tablet is a white, biconvex, round, film-coated tablet, with a diameter of 7.1 mm and a thickness of 2.7 mm, imprinted with ‘15’ on one side, and ‘102’ and ’15 mg’ on the other side, in grey ink. 

Lonsurf 20 mg/8.19 mg film-coated tablets
The tablet is a pale red, biconvex, round, film-coated tablet, with a diameter of 7.6 mm and a thickness of 3.2 mm, imprinted with ‘20’ on one side, and ‘102’ and ‘20 mg’ on the other side, in grey ink.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Colorectal cancer</u></p><p>&nbsp;</p><p>Lonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.</p><p>&nbsp;</p><p>Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer &nbsp;who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti‑EGFR agents.</p><p>&nbsp;</p><p><u>Gastric cancer</u></p><p>&nbsp;</p><p>Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General:</p><p>&nbsp;</p><p>Lonsurf should be prescribed by physicians experienced in the administration of anticancer therapy.</p><p><u>Method of Administration:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>LONSURF&nbsp;</em>is a cytotoxic drug. Follow applicable special handling and disposal procedures (see section 6.6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablets should be swallowed whole.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets should not be broken or crushed, if possible. This might produce powder that can contaminate workplace surfaces.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If tablet must be cut or crushed, this should be done by a professional trained personal experienced in safe handling of hazardous drugs using an appropriate equipment and safety procedures.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended starting dose of Lonsurf in adults, <u>as monotherapy or in combination with bevacizumab,</u> is 35 mg/m<sup>2</sup>/dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle until disease progression or &nbsp;unacceptable toxicity (see section 4.4).</p><p>When Lonsurf is used in combination with bevacizumab for the treatment of metastatic CRC, the dose of bevacizumab is 5 mg/kg of body weight given once every 2 weeks. Please refer to the full product information for bevacizumab.</p><p>&nbsp;</p><p>The dose is calculated according to body surface area (BSA) (see Table 1).&nbsp; The dose must not exceed 80 mg/dose.&nbsp;</p><p>&nbsp;</p><p>If doses were missed or held, the patient must not make up for missed doses.</p><p>&nbsp;</p><p><strong>Table 1 - Starting dose calculation according to (BSA)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:590px"><thead><tr><td rowspan="2"><p><strong>Starting dose</strong></p></td><td rowspan="2"><p><strong>BSA<br />(m<sup>2</sup>)</strong></p></td><td rowspan="2"><p><strong>Dose in mg<br />(2x daily)</strong></p></td><td colspan="2"><p><strong>Tablets per dose</strong></p><p><strong>(2x daily)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Total daily<br />dose (mg)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>15 mg/6.14 mg</strong></p></td><td style="vertical-align:bottom"><p><strong>20 mg/8.19 mg</strong></p></td></tr></thead><tbody><tr><td rowspan="10" style="vertical-align:top"><p>35 mg/m<sup>2</sup></p></td><td><p>&lt; 1.07</p></td><td><p>35</p></td><td><p>1</p></td><td><p>1</p></td><td><p>70</p></td></tr><tr><td><p>1.07 - 1.22</p></td><td><p>40</p></td><td><p>0</p></td><td><p>2</p></td><td><p>80</p></td></tr><tr><td><p>1.23 - 1.37</p></td><td><p>45</p></td><td><p>3</p></td><td><p>0</p></td><td><p>90</p></td></tr><tr><td><p>1.38 - 1.52</p></td><td><p>50</p></td><td><p>2</p></td><td><p>1</p></td><td><p>100</p></td></tr><tr><td><p>1.53 - 1.68</p></td><td><p>55</p></td><td><p>1</p></td><td><p>2</p></td><td><p>110</p></td></tr><tr><td><p>1.69 - 1.83</p></td><td><p>60</p></td><td><p>0</p></td><td><p>3</p></td><td><p>120</p></td></tr><tr><td><p>1.84 - 1.98</p></td><td><p>65</p></td><td><p>3</p></td><td><p>1</p></td><td><p>130</p></td></tr><tr><td><p>1.99 - 2.14</p></td><td><p>70</p></td><td><p>2</p></td><td><p>2</p></td><td><p>140</p></td></tr><tr><td><p>2.15 - 2.29</p></td><td><p>75</p></td><td><p>1</p></td><td><p>3</p></td><td><p>150</p></td></tr><tr><td><p>&ge; 2.30</p></td><td><p>80</p></td><td><p>0</p></td><td><p>4</p></td><td><p>160</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Recommended dose adjustments</em></p><p><u>&nbsp;</u></p><p>Dosing adjustments may be required based on individual safety and tolerability.</p><p>&nbsp;</p><p>A maximum of 3 dose reductions are permitted to a minimum dose of 20 mg/m<sup>2</sup> twice daily. Dose escalation is not permitted after it has been reduced.</p><p>&nbsp;</p><p>In the event of haematological and/or non-haematological toxicities patients should follow the dose interruption, resumption and reduction criteria stated in Table 2, Table 3 and Table 4.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>2 - Dose interruption and resumption criteria for</strong></p><p><strong>haematological toxicities related to myelosuppression</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:bottom"><p>Parameter</p></td><td style="vertical-align:bottom"><p>Interruption criteria</p></td><td style="vertical-align:bottom"><p>Resumption criteriaa</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Neutrophils</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 0.5&nbsp;&acute; 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>&sup3; 1.5&nbsp;&acute; 10<sup>9</sup>/L</p></td></tr><tr><td style="vertical-align:top"><p>Platelets</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 50&nbsp;&acute; 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>&sup3; 75&nbsp;&acute; 10<sup>9</sup>/L</p></td></tr></tbody></table><p><sup>a</sup> Resumption criteria applied to the start of the next cycle for all patients regardless of whether or not the interruption criteria were met.</p><p><u>&nbsp;</u></p><p><strong>Table 3 - Recommended dose modifications for Lonsurf in case of</strong></p><p><strong>haematological and non-haematological adverse reactions</strong></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Recommended dose modifications</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Febrile neutropenia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE* Grade 4 neutropenia (&lt;&nbsp;0.5&nbsp;x&nbsp;10<sup>9</sup>/L) &nbsp;or thrombocytopenia (&lt; &nbsp;25&nbsp;&acute;&nbsp;10<sup>9</sup>/L) that results in more than 1 week&rsquo;s delay in start of next cycle</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE* non-haematologic Grade 3 or Grade 4 adverse reaction; except for Grade 3 nausea and/or vomiting controlled by antiemetic therapy or diarrhoea responsive to antidiarrhoeal medicinal products</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interrupt dosing until toxicity resolves to Grade 1 or baseline.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When resuming dosing, decrease the dose level by 5 mg/m<sup>2</sup>/dose from the previous dose level (Table 4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose reductions are permitted to a minimum dose of 20&nbsp;mg/m<sup>2</sup>/dose twice daily. (or 15 mg/m2/dose twice daily in severe renal impairment).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not increase dose after it has been reduced.</p><p>&nbsp;</p></td></tr></tbody></table><p>* Common terminology criteria for adverse events</p><p>&nbsp;</p><p><strong>Table&nbsp;4 - Dose reductions according to (BSA)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:573px"><thead><tr><td rowspan="2"><p>Reduced dose</p></td><td rowspan="2"><p>BSA<br />(m<sup>2</sup>)</p></td><td rowspan="2"><p>Dose in mg<br />(2x daily)</p></td><td colspan="2"><p>Tablets per dose</p><p>(2x daily)</p></td><td rowspan="2"><p>Total daily<br />dose (mg)</p></td></tr><tr><td style="vertical-align:bottom"><p>15 mg/6.14 mg</p></td><td style="vertical-align:bottom"><p>20 mg/8.19 mg</p></td></tr></thead><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Level 1 dose reduction:&nbsp; From 35 mg/m<sup>2</sup> to 30 mg/m<sup>2</sup></strong></p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p><strong>30 mg/m<sup>2</sup></strong></p></td><td style="vertical-align:top"><p>&lt; 1.09</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>1.09 - 1.24</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>70</p></td></tr><tr><td style="vertical-align:top"><p>1.25 - 1.39</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>80</p></td></tr><tr><td style="vertical-align:top"><p>1.40 - 1.54</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p>1.55 - 1.69</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>1.70 - 1.94</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>110</p></td></tr><tr><td style="vertical-align:top"><p>1.95 - 2.09</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>120</p></td></tr><tr><td style="vertical-align:top"><p>2.10 - 2.28</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>130</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 2.29</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>140</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Level 2 dose reduction:&nbsp; From 30 mg/m<sup>2</sup> to 25 mg/m<sup>2</sup></strong></p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p><strong>25 mg/m<sup>2</sup></strong></p></td><td style="vertical-align:top"><p>&lt; 1.10</p></td><td style="vertical-align:top"><p>25a</p></td><td style="vertical-align:top"><p>2<sup>a</sup></p></td><td style="vertical-align:top"><p>1<sup>a</sup></p></td><td style="vertical-align:top"><p>50<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>1.10 - 1.29</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>1.30 - 1.49</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>70</p></td></tr><tr><td style="vertical-align:top"><p>1.50 - 1.69</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>80</p></td></tr><tr><td style="vertical-align:top"><p>1.70 - 1.89</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p>1.90 - 2.09</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>2.10 - 2.29</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>110</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 2.30</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>120</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Level 3 dose reduction:&nbsp; From 25 mg/m<sup>2</sup> to 20 mg/m<sup>2</sup></strong></p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p><strong>20 mg/m<sup>2</sup></strong></p></td><td style="vertical-align:top"><p>&lt; 1.14</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>40</p></td></tr><tr><td style="vertical-align:top"><p>1.14 &ndash; 1.34</p></td><td style="vertical-align:top"><p>25<sup>a</sup></p></td><td style="vertical-align:top"><p>2<sup>a</sup></p></td><td style="vertical-align:top"><p>1<sup>a</sup></p></td><td style="vertical-align:top"><p>50<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>1.35 &ndash; 1.59</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>1.60 &ndash; 1.94</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>70</p></td></tr><tr><td style="vertical-align:top"><p>1.95 &ndash; 2.09</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>80</p></td></tr><tr><td style="vertical-align:top"><p>2.10 &ndash; 2.34</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>90</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 2.35</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>100</p></td></tr></tbody></table><p><sup>a</sup> At a total daily dose of 50 mg, patients should take 1 x 20 mg/8.19 mg tablet in the morning and 2&nbsp;x 15 mg/6.14 mg tablets in the evening.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Mild renal impairment (CrCl 60 to 89 mL/min) or moderate renal impairment (CrCl 30 to 59&nbsp;mL/min)</em></p><p>No adjustment of the starting dose is recommended in patients with mild or moderate renal impairment (see sections 4.4 and 5.2).</p><p><em>&nbsp;</em></p><p><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe renal impairment (CrCl 15 to 29 mL/min) </em></p><p><em>For patients with severe renal impairment a starting dose of 20 mg/m2 twice daily is recommended (see sections 4.4 and 5.2). One dose reduction to a minimum dose of 15 mg/m2 twice daily is permitted based on individual safety and tolerability (see Table 5). Dose escalation is not permitted after it has been reduced.</em></p><p><em>In the event of haematological and/or non-haematological toxicities patients should follow the dose interruption, resumption and reduction criteria stated in Table 2, Table 3 and Table 5.</em></p><p><em>&nbsp;</em></p><p><em>Table 5 &ndash; Starting dose and dose reduction in patients with severe renal impairment according to (BSA)</em></p><p><em>&nbsp;</em></p><p><strong><em>&nbsp;</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:573px"><thead><tr><td rowspan="2"><p><strong><em>Reduced dose</em></strong></p></td><td rowspan="2"><p><strong><em>BSA<br />(m<sup>2</sup>)</em></strong></p></td><td rowspan="2"><p><strong><em>Dose in mg<br />(2x daily)</em></strong></p></td><td colspan="2"><p><strong><em>Tablets per dose</em></strong></p><p><strong><em>(2x daily)</em></strong></p></td><td rowspan="2"><p><strong><em>Total daily<br />dose (mg)</em></strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong><em>15 mg/6.14 mg</em></strong></p></td><td style="vertical-align:bottom"><p><strong><em>20 mg/8.19 mg</em></strong></p></td></tr></thead><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong><em>Starting dose</em></strong></p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p><strong><em>20 mg/m<sup>2</sup></em></strong></p></td><td style="vertical-align:top"><p><em>&lt; 1.14</em></p></td><td style="vertical-align:top"><p><em>20</em></p></td><td style="vertical-align:top"><p><em>0</em></p></td><td style="vertical-align:top"><p><em>1</em></p></td><td style="vertical-align:top"><p><em>40</em></p></td></tr><tr><td style="vertical-align:top"><p><em>1.14 &ndash; 1.34</em></p></td><td style="vertical-align:top"><p><em>25<sup>a</sup></em></p></td><td style="vertical-align:top"><p><em>2<sup>a</sup></em></p></td><td style="vertical-align:top"><p><em>1<sup>a</sup></em></p></td><td style="vertical-align:top"><p><em>50<sup>a</sup></em></p></td></tr><tr><td style="vertical-align:top"><p><em>1.35 &ndash; 1.59</em></p></td><td style="vertical-align:top"><p><em>30</em></p></td><td style="vertical-align:top"><p><em>2</em></p></td><td style="vertical-align:top"><p><em>0</em></p></td><td style="vertical-align:top"><p><em>60</em></p></td></tr><tr><td style="vertical-align:top"><p><em>1.60 &ndash; 1.94</em></p></td><td style="vertical-align:top"><p><em>35</em></p></td><td style="vertical-align:top"><p><em>1</em></p></td><td style="vertical-align:top"><p><em>1</em></p></td><td style="vertical-align:top"><p><em>70</em></p></td></tr><tr><td style="vertical-align:top"><p><em>1.95 &ndash; 2.09</em></p></td><td style="vertical-align:top"><p><em>40</em></p></td><td style="vertical-align:top"><p><em>0</em></p></td><td style="vertical-align:top"><p><em>2</em></p></td><td style="vertical-align:top"><p><em>80</em></p></td></tr><tr><td style="vertical-align:top"><p><em>2.10 &ndash; 2.34</em></p></td><td style="vertical-align:top"><p><em>45</em></p></td><td style="vertical-align:top"><p><em>3</em></p></td><td style="vertical-align:top"><p><em>0</em></p></td><td style="vertical-align:top"><p><em>90</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&ge; 2.35</em></p></td><td style="vertical-align:top"><p><em>50</em></p></td><td style="vertical-align:top"><p><em>2</em></p></td><td style="vertical-align:top"><p><em>1</em></p></td><td style="vertical-align:top"><p><em>100</em></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong><em>Dose reduction:&nbsp; From 20 mg/m<sup>2</sup> to 15 mg/m<sup>2</sup></em></strong></p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p><strong><em>15 mg/m<sup>2</sup></em></strong></p></td><td style="vertical-align:top"><p><em>&lt; 1.15</em></p></td><td style="vertical-align:top"><p><em>15</em></p></td><td style="vertical-align:top"><p><em>1</em></p></td><td style="vertical-align:top"><p><em>0</em></p></td><td style="vertical-align:top"><p><em>30</em></p></td></tr><tr><td style="vertical-align:top"><p><em>1.15 &ndash; 1.49</em></p></td><td style="vertical-align:top"><p><em>20</em></p></td><td style="vertical-align:top"><p><em>0</em></p></td><td style="vertical-align:top"><p><em>1</em></p></td><td style="vertical-align:top"><p><em>40</em></p></td></tr><tr><td style="vertical-align:top"><p><em>1.50 &ndash; 1.84</em></p></td><td style="vertical-align:top"><p><em>25<sup>a</sup></em></p></td><td style="vertical-align:top"><p><em>2<sup>a</sup></em></p></td><td style="vertical-align:top"><p><em>1<sup>a</sup></em></p></td><td style="vertical-align:top"><p><em>50<sup>a</sup></em></p></td></tr><tr><td style="vertical-align:top"><p><em>1.85 &ndash; 2.09</em></p></td><td style="vertical-align:top"><p><em>30</em></p></td><td style="vertical-align:top"><p><em>2</em></p></td><td style="vertical-align:top"><p><em>0</em></p></td><td style="vertical-align:top"><p><em>60</em></p></td></tr><tr><td style="vertical-align:top"><p><em>2.10 &ndash; 2.34</em></p></td><td style="vertical-align:top"><p><em>35</em></p></td><td style="vertical-align:top"><p><em>1</em></p></td><td style="vertical-align:top"><p><em>1</em></p></td><td style="vertical-align:top"><p><em>70</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&ge; 2.35</em></p></td><td style="vertical-align:top"><p><em>40</em></p></td><td style="vertical-align:top"><p><em>0</em></p></td><td style="vertical-align:top"><p><em>2</em></p></td><td style="vertical-align:top"><p><em>80</em></p></td></tr></tbody></table><p>a At a total daily dose of 50 mg, patients should take 1 x 20 mg/8.19 mg tablet in the morning and 2 x 15 mg/6.14 mg tablets in the evening.</p><p><em>&nbsp;</em></p><p><u>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; End stage renal disease (CrCl below 15 mL/min or requiring dialysis)</u></p><p>Administration is not recommended in patients with end stage renal disease as there are no data available for these patients (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Hepatic </em><em>impairment</em></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Mild hepatic impairment</em></p><p>No adjustment of the starting dose is recommended in patients with mild hepatic impairment. (see section 5.2).</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Moderate or severe hepatic impairment</em></p><p>Administration is not recommended in patients with baseline moderate or severe hepatic impairment (National Cancer Institute [NCI] Criteria Group C and D defined by total bilirubin &gt;&nbsp;1.5&nbsp;x&nbsp;ULN) as, a higher incidence of Grade 3 or 4 hyperbilirubinaemia is observed in patients with baseline moderate hepatic impairment, although this is based on very limited data (see sections 4.4 and 5.2).</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Elderly </em></p><p><em>&nbsp;</em></p><p>No adjustment of the starting dose is required in patients &ge; 65 years old (see sections 4.8, 5.1 and 5.2).</p><p>Efficacy and safety data in patients over 75 years old is limited.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>There is no relevant use of Lonsurf in the paediatric population for the indication of metastatic colorectal cancer and metastatic gastric cancer.</p><p><u>&nbsp;</u></p><p><em>Race&nbsp; </em></p><p><em>&nbsp;</em></p><p>No adjustment of the starting dose is required on the basis of patient&rsquo;s race (see sections 5.1 and 5.2).&nbsp; There is limited data on Lonsurf in Black/African American patients but there is no biological rationale to expect any difference between this subgroup and the overall population.&nbsp;</p><p><u>&nbsp;</u></p><p><u>Method of administration </u></p><p><u>&nbsp;</u>&nbsp;Lonsurf is for oral use. The tablets must be taken with a glass of water within 1 hour after completion of the morning and evening meals.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Bone marrow suppression</u></p><p><u>&nbsp;</u></p><p>Lonsurf caused an increase in the incidence of myelosuppression including anaemia, neutropenia, leukopenia, and thrombocytopenia.</p><p>&nbsp;</p><p>Complete blood cell counts must be obtained prior to initiation of therapy and as needed to monitor toxicity, but at a minimum, prior to each treatment cycle.</p><p>&nbsp;</p><p>Treatment must not be started if the absolute neutrophil count is &lt; 1.5&nbsp;&acute;10<sup>9</sup>/L, if the platelet counts are &le;&nbsp;75&acute; &nbsp;10<sup>9</sup>/L, or if the patient has an unresolved Grade 3 or 4 non-haematological clinically relevant toxicity from prior therapies.</p><p><em>&nbsp;</em></p><p>Serious infections have been reported following treatment with Lonsurf (see section 4.8). Given that the majority were reported in the context of bone marrow suppression, the patient&rsquo;s condition should be monitored closely, and appropriate measures, such as antimicrobial agents and granulocyte-colony stimulating factor (G-CSF), should be administered as clinically indicated. In RECOURSE,TAGS and SUNLIGHT studies, 9.4%,17.3% and 19.5% of patients in the Lonsurf group respectively received G-CSF mainly for therapeutic use. In the SUNLIGHT study, 29.3% of patients in the Lonsurf with bevacizumab group received G-CSF including 16.3% for therapeutic use.</p><p><u>&nbsp;</u></p><p><u>Gastrointestinal toxicity</u></p><p><u>&nbsp;</u></p><p>Lonsurf caused an increase in the incidence of gastrointestinal toxicities including nausea, vomiting and diarrhoea.</p><p>&nbsp;</p><p>Patients with nausea, vomiting, diarrhoea and other gastrointestinal toxicities should be carefully monitored, and anti-emetic, anti-diarrhoeal and other measures, such as fluid/electrolyte replacement therapy, should be administered as clinically indicated. Dose modifications (delay and/or reduction) should be applied as necessary (see section 4.2).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>Lonsurf is not recommended for use in patients with end-stage renal disease (creatinine clearance [CrCl] &lt; 15 mL/min or requiring dialysis), as Lonsurf has not been studied in these patients (see section 5.2).</p><p>The global incidence of adverse events (AEs) is similar in normal renal function (CrCl &ge; 90 mL/min), mild (CrCl = 60 to 89 mL/min) or moderate (CrCl = 30 to 59 mL/min) renal impairment subgroups. However, the incidence of serious, severe AEs and AEs leading to dose modification tends to increase with advancing levels of renal impairment. In addition, a higher exposure of trifluridine and tipiracil hydrochloride was observed in patients with moderate renal impairment, compared with patients with normal renal function or patients with mild renal impairment (see section 5.2).</p><p>Patients with severe renal impairment (CrCl = 15 to 29 mL/min) and adjusted starting dose of 20&nbsp;mg/m<sup>2</sup> twice daily had a safety profile consistent with the safety profile of Lonsurf in patients with normal renal function or mild renal impairment. Their exposure to trifluridine was similar to that of patients with normal renal function and their exposure to tipiracil hydrochloride was increased compared to patients with normal renal function, mild and moderate renal impairment (see sections 4.2 and 5.2).</p><p>Patients with renal impairment should be monitored closely when being treated with Lonsurf; patients with moderate or severe renal impairment should be more frequently monitored for haematological toxicities.</p><p><u>&nbsp;</u></p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Lonsurf is not recommended for use in patients with baseline moderate or severe hepatic impairment (National Cancer Institute [NCI] Criteria Group C and D defined by total bilirubin &gt;&nbsp;1.5&nbsp;x&nbsp;ULN), as a higher incidence of Grade 3 or 4 hyperbilirubinaemia is observed in patients with baseline moderate hepatic impairment, although this is based on very limited data (see section 5.2).</p><p>&nbsp;</p><p><u>Proteinuria</u></p><p>&nbsp;</p><p>Monitoring of proteinuria by dipstick urinalysis is recommended prior to starting and during therapy (see section 4.8).</p><p>&nbsp;</p><p><u>Lactose intolerance</u></p><p>&nbsp;</p><p>Lonsurf contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em> studies indicated that trifluridine, tipiracil hydrochloride and 5-[trifluoromethyl] uracil (FTY) did not inhibit the activity of human cytochrome P450 (CYP) isoforms. <em>In vitro</em> evaluation indicated that trifluridine, tipiracil hydrochloride and FTY had no inductive effect on human CYP isoforms (see section 5.2).</p><p>&nbsp;</p><p><em>In vitro</em> studies indicated that trifluridine is a substrate for the nucleoside transporters CNT1, ENT1 and ENT2. Therefore, caution is required when using medicinal products that interact with these transporters. Tipiracil hydrochloride was a substrate for OCT2 and MATE1, therefore, the concentration might be increased when Lonsurf is administered concomitantly with inhibitors of OCT2 or MATE1.</p><p>&nbsp;</p><p>Caution is required when using medicinal products that are human thymidine kinase substrates, e.g., zidovudine.&nbsp; Such medicinal products, if used concomitantly with Lonsurf, may compete with the effector, trifluridine, for activation via thymidine kinases. Therefore, when using antiviral medicinal products that are human thymidine kinase substrates, monitor for possible decreased efficacy of the antiviral medicinal product, and consider switching to an alternative antiviral medicinal product that is not a human thymidine kinase substrate, such as lamivudine, didanosine and abacavir (see section 5.1).</p><p>&nbsp;</p><p>It is unknown whether Lonsurf may reduce the effectiveness of hormonal contraceptives. Therefore, women using hormonal contraceptive must also use a barrier contraceptive method.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in males and females</u></p><p>&nbsp;</p><p>Based on findings in animals, trifluridine may cause foetal harm when administered to pregnant women. Women should avoid becoming pregnant while taking Lonsurf and for up to 6 months after ending treatment. Therefore, women of child-bearing potential must use highly effective contraceptive measures while taking Lonsurf and for 6 months after stopping treatment. It is currently unknown whether Lonsurf may reduce the effectiveness of hormonal contraceptives, and therefore women using hormonal contraceptives should add a barrier contraceptive method.</p><p>Men with a partner of child-bearing potential must use effective contraception during treatment and for up to 6 months after discontinuation of treatment.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Pregnancy category D.</p><p>&nbsp;</p><p>There are no available data from the use of Lonsurf in pregnant women. Based on the mechanism of action, trifluridine is suspected to cause congenital malformations when administered during pregnancy. Studies in animals have shown reproductive toxicity (see section 5.3). Lonsurf should not be used during pregnancy unless the clinical condition of the woman requires treatment with Lonsurf.</p><p>&nbsp;</p><p><u>Breast-feeding </u></p><p>&nbsp;</p><p>It is unknown whether Lonsurf or its metabolites are excreted in human milk. Studies in animals have shown excretion of trifluridine, tipiracil hydrochloride and/or their metabolites in milk (see section&nbsp;5.3). A risk to the suckling child cannot be excluded. Breast-feeding should be discontinued during treatment with Lonsurf.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no data available on the effects of Lonsurf on human fertility. Results of animal studies did not indicate an effect of Lonsurf on male or female fertility (see section 5.3). Patients who wish to conceive a child should be advised to seek reproductive counselling and cryo-conservation of either the ovum or sperm prior to starting Lonsurf treatment.</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lonsurf has minor influence on the ability to drive and use machines. Fatigue, dizziness or malaise may occur during treatment (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p><u>&nbsp;</u></p><p>The most serious<strong> </strong>observed<strong> </strong>adverse<strong> </strong>reactions in patients receiving Lonsurf are bone marrow suppression and gastrointestinal toxicity (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Lonsurf as monotherapy </em></p><p>The safety profile of Lonsurf as monotherapy is based on the pooled data from 1114 patients with metastatic colorectal or gastric cancer in controlled phase III clinical studies.</p><p>The most common adverse reactions (&ge; 30%) are neutropenia (53% [34% &ge; Grade 3]), nausea (31% [1% &ge; Grade 3]), fatigue (31% [4% &ge; Grade 3]), and anaemia (30% [11% &ge; Grade 3]).</p><p>&nbsp;</p><p>The most common adverse reactions (&ge; 2%) that resulted in treatment discontinuation, dose reduction, dose delay, or dose interruption were neutropenia, anaemia, fatigue, leukopenia, thrombocytopenia, diarrhoea, and nausea.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Lonsurf in combination with bevacizumab</u></em>&nbsp;</p><p><u>The safety profile of Lonsurf in combination with bevacizumab is based on the data from 246 patients with metastatic colorectal cancer in the controlled phase III clinical study (SUNLIGHT).</u>&nbsp;</p><p><u>The most common adverse reactions (&ge; 30%) are neutropenia (69% [48% &ge; Grade 3]), fatigue (35% [3% &ge; Grade 3]), and nausea (33% [1% &ge; Grade 3]).</u>&nbsp;</p><p><u>The most common adverse reactions (&ge; 2%) that resulted in treatment discontinuation, dose reduction, dose delay, or dose interruption of Lonsurf when used in combination with bevacizumab were neutropenia, fatigue, thrombocytopenia, nausea and anaemia.</u>&nbsp;</p><p><u>When Lonsurf is used in combination with bevacizumab, the frequency of the following adverse reactions was increased compared to Lonsurf as monotherapy: neutropenia (69% vs 53%), severe neutropenia (48% vs 34%), thrombocytopenia (24% vs 16%), stomatitis (11% vs 6%).</u>&nbsp;</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The adverse reactions observed from the 533 treated patients with metastatic colorectal cancer in the placebo-controlled Phase III (RECOURSE) clinical study,the 335 treated patients with metastatic gastric cancer in the placebo-controlled Phase III (TAGS) clinical study, the 246 patients treated with Lonsurf in monotherapy and the 246 patients treated with Lonsurf in combination with bevacizumab for metastatic colorectal cancer in the controlled Phase III (SUNLIGHT) clinical study, are shown in Table-6. They are classified according to System Organ Class (SOC) and the appropriate Medical Dictionary for Regulatory (MedDRA) term is used to describe a certain drug reaction and its synonyms and related conditions.</p><p><u>Adverse reactions known to occur with Lonsurf given alone or with bevacizumab may occur during treatment with these medicinal products in combination, even if these reactions were not reported in clinical trials with combination therapy.</u>&nbsp;</p><p>Adverse reactions are grouped according to their frequencies. Frequency groups are defined by the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge;1/1,000 to &lt; 1/100) ); and rare (&ge; 1/10 000 to <u>&lt; </u><s> </s><u>1/1 000</u>)</p><p>&nbsp;</p><p>Within each frequency group, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 6 - Adverse reactions reported in clinical studies in patients treated with Lonsurf</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom"><p><strong><u>System Organ Class (MedDRA)</u></strong><strong><u><sup>a</sup></u></strong>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong><u>Adverse reactions</u></strong>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong><u>Frequency</u></strong>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong><u>Monotherapy</u></strong>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong><u>Combination with bevacizumab</u></strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Infections and infestations</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Lower respiratory tract infection</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Neutropenic sepsis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Biliary tract infection</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Infection</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Urinary tract infection</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Bacterial infection</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Candida infection</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Conjunctivitis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Herpes zoster</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Influenza</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Upper respiratory tract infection</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Enteritis infectious</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Septic shock</u><u><sup>b</sup></u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Gingivitis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Tinea pedis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Cancer pain</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Anaemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Neutropenia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Leukopenia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Thrombocytopenia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Febrile neutropenia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Lymphopenia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Pancytopenia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Erythropenia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Leukocytosis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Monocytopenia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Monocytosis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Granulocytopenia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><u>Metabolism and nutrition disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Decreased appetite</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Hypoalbuminaemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Dehydration</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hyperglycaemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hyperkalaemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hypocalcaemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hypokalaemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hyponatraemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hypophosphataemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Gout</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hypernatraemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Psychiatric disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Anxiety</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Insomnia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Nervous system disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Dysgeusia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Dizziness</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Headache</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Neuropathy peripheral</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Paraesthesia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Lethargy</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Neurotoxicity</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Burning sensation</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Dysaesthesia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hyperaesthesia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hypoaesthesia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Syncope</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Eye disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Cataract</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Diplopia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Dry eye</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Vision blurred</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Visual acuity reduced</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Ear and labyrinth disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Vertigo</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Ear discomfort</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Cardiac disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Angina pectoris</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Arrhythmia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Palpitations</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Vascular disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hypertension</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Flushing</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hypotension</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Embolism</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><u>Respiratory, thoracic and mediastinal disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Dyspnoea</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Pulmonary embolism</u><u><sup>b</sup></u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Dysphonia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Cough</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Epistaxis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rhinorrhoea</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Oropharyngeal pain</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Pleural effusion</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Gastrointestinal disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Diarrhoea</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Vomiting</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Nausea</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Abdominal pain</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Stomatitis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Constipation</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Ileus</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Gastrointestinal haemorrhage</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Colitis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Mouth ulceration</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Oral disorder</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Abdominal distension</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Anal inflammation</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Dyspepsia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Flatulence</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Gastritis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Gastrooesophageal reflux disease</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Glossitis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Impaired gastric emptying</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Retching</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Tooth disorder</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Ascites</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Pancreatitis acute</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Subileus</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Breath odour</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Buccal polyp</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Enterocolitis haemorrhagic</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Gingival bleeding</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Oesophagitis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Periodontal disease</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Proctalgia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Reflux gastritis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Hepatobiliary disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hyperbilirubinaemia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hepatotoxicity</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Biliary dilatation</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Alopecia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Dry skin</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Pruritus</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rash</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Nail disorder</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Palmar-plantar erythrodysaesthesia syndrome</u><u><sup>c</sup></u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Acne</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hyperhidrosis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Urticaria</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Blister</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Erythema</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Photosensitivity reaction</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Skin exfoliation</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><u>Musculoskeletal and connective tissue disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Arthralgia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Myalgia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Muscular weakness</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Pain in extremity</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Bone pain</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Limb discomfort</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Muscle spasms</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Joint swelling</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Renal and urinary disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Proteinuria</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Renal failure</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Haematuria</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Micturition disorder</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Cystitis noninfective</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Leukocyturia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Reproductive system and breast disorders</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Menstrual disorder</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><u>General disorders and administration site conditions</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Fatigue</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Very common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Pyrexia</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Mucosal inflammation</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Malaise</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Oedema</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>General physical health deterioration</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Pain</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Feeling of body temperature change</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Xerosis</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Investigations</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Weight decreased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Hepatic enzyme increased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Blood alkaline phosphatase increased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Common</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Blood lactate dehydrogenase increased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>C-reactive protein increased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Blood creatinine increased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Blood urea increased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Haematocrit decreased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>International normalised ratio increased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Uncommon</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Activated partial thromboplastin time prolonged</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Electrocardiogram QT prolonged</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Protein total decreased</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>Rare</u>&nbsp;</p></td><td style="vertical-align:top"><p><u>-</u>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>a.&nbsp;&nbsp;&nbsp; Different MedDRA preferred terms that were considered clinically similar have been grouped into a single term.</p><p>b.&nbsp;&nbsp; Fatal cases have been reported.</p><p>c.&nbsp;&nbsp;&nbsp; Hand-foot skin reaction.</p><p><strong>&nbsp;</strong></p><p><u>Elderly</u></p><p>&nbsp;</p><p>Patients 65 years of age or older who received Lonsurf as monotherapy had a higher incidence <u>(&ge; 5%) </u>of the following <u>treatment-related adverse </u>events compared to patients younger than 65 years:</p><p>neutropenia (58.9% vs 48.2%), severe neutropenia (41.3% vs 27.9%), anaemia (36.5% vs 25.2%), severe anaemia (14.1% vs 8.9%), decreased appetite (22.6% vs 17.4%), and thrombocytopenia (21.4% vs 12.1%).</p><p><u>When Lonsurf is used in combination with bevacizumab, patients 65 years of age or older had a higher incidence (&ge; 5%) of the following treatment-related adverse events<strong> </strong>compared to patients younger than 65 years: neutropenia (75.0% vs 65.1%), severe neutropenia (57.0% vs 41.8%), fatigue (39.0% vs 32.2%), thrombocytopenia (28.0% vs 20.5%), and stomatitis (14.0% vs 8.9%).</u>&nbsp;</p><p>&nbsp;</p><p><u>Infections</u></p><p><u>&nbsp;</u></p><p>In the Phase III <u>placebo-controlled </u>clinical studies, treatment-related infections occurred more frequently in Lonsurf-treated patients (5.8%) compared to those receiving placebo (1.8%). <u>In the clinical study in combination with bevacizumab, treatment-related infections occurred similarly in patients who received Lonsurf with bevacizumab (2.8%) compared to Lonsurf-treated patients (2.4%).</u>&nbsp;</p><p>&nbsp;</p><p><u>Proteinuria</u></p><p><u>&nbsp;</u></p><p><u>In the Phase III placebo-controlled clinical studies, </u>treatment-related proteinuria occurred more frequently in Lonsurf-treated patients (1.8%) compared to those receiving placebo (0.9%), all of which were Grade 1 or 2 in severity (see section 4.4).</p><p><u>In the clinical study in combination with bevacizumab, one patient who received Lonsurf with bevacizumab (0.4%) reported a treatment-related proteinuria which was Grade 2 and none among the Lonsurf-treated patients (see section 4.4).</u>&nbsp;</p><p>&nbsp;</p><p><u>Radiotherapy</u></p><p><u>&nbsp;</u></p><p>There was a slightly higher incidence of overall haematological and myelosuppression-related adverse reactions for patients who received prior radiotherapy compared to patients without prior radiotherapy in RECOURSE (54.6% versus 49.2%, respectively), of note febrile neutropenia was higher in Lonsurf-treated patients who received prior radiotherapy vs. those that did not.</p><p><u>In the clinical study in combination with bevacizumab, no increase of incidence of overall haematological and myelosuppression-related adverse reactions was observed for patients who received prior radiotherapy compared to patients without prior radiotherapy in both arms in SUNLIGHT: Lonsurf with bevacizumab (73.7% versus 77.4%) and in Lonsurf-treated patients (64.7% versus 67.7%).</u>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Post-marketing experience in patients with unresectable advanced or recurrent colorectal cancer</u></p><p><u>&nbsp;</u></p><p>There have been reports of interstitial lung disease in patients receiving Lonsurf post approval.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><ul><li>Saudi Arabia:</li></ul><p><!--[if gte vml 1]><v:rect
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:-1.6pt;margin-top:6.85pt;width:453.75pt;height:111.25pt;
 text-indent:0;z-index:251651072'/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>- The National Pharmacovigilance Center (NPC)</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center&nbsp;: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email&nbsp;: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website&nbsp;: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Other GCC states:</p><p><!--[if gte vml 1]><v:rect
 id="_x0000_s1028" style='position:absolute;left:0;text-align:left;
 margin-left:-1.6pt;margin-top:7.25pt;width:453.75pt;height:23pt;text-indent:0;
 z-index:251653120'>
 <v:textbox style='mso-next-textbox:#_x0000_s1028'/>
</v:rect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest dose of Lonsurf administered in clinical studies was 180 mg/m<sup>2</sup> per day.</p><p>&nbsp;</p><p>The adverse drug reactions reported in association with overdoses were consistent with the established safety profile.</p><p>&nbsp;</p><p>The primary anticipated complication of an overdose is bone marrow suppression.</p><p>&nbsp;</p><p>There is no known antidote for an overdose of Lonsurf.</p><p>&nbsp;</p><p>Medical management of an overdose should include customary therapeutic and supportive medical intervention aimed at correcting the presenting clinical manifestations and preventing their possible complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic agents, antimetabolites, ATC code: L01BC59</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Lonsurf is comprised of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride, at a molar ratio 1:0.5 (weight ratio, 1:0.471).</p><p>&nbsp;</p><p>Following uptake into cancer cells, trifluridine, is phosphorylated by thymidine kinase, further metabolised in cells to a deoxyribonucleic acid DNA substrate, and incorporated directly into DNA, thereby interfering with DNA function to prevent cell proliferation.</p><p>&nbsp;</p><p>However, trifluridine is rapidly degraded by TPase and readily metabolised by a first-pass effect following oral administration, hence the inclusion of the TPase inhibitor, tipiracil hydrochloride.</p><p>&nbsp;</p><p>In nonclinical studies, trifluridine/tipiracil hydrochloride demonstrated&nbsp;antitumour activity against both 5-fluorouracil (5-FU) sensitive and resistant colorectal cancer cell lines.&nbsp;</p><p>&nbsp;</p><p>The cytotoxic activity of trifluridine/tipiracil hydrochloride against several human tumour xenografts correlated highly with the amount of trifluridine incorporated into DNA, suggesting this as the primary mechanism of action.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>Lonsurf had no clinically relevant effect on QT/QTc prolongation compared with placebo in an open label study in patients with advanced solid tumours.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em>Metastatic colorectal cancer</em></p><p><em>&nbsp;</em></p><p><em><u>Randomised phase III study of Lonsurf as monotherapy versus placebo</u></em>&nbsp;</p><p>The clinical efficacy and safety of Lonsurf were evaluated in an international, randomised, double-blind, placebo-controlled Phase III study (RECOURSE) in patients with previously treated metastatic colorectal cancer. The primary efficacy endpoint was overall survival (OS), and supportive efficacy endpoints were progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR).</p><p>&nbsp;</p><p>In total, 800 patients were randomised 2:1 to receive Lonsurf (N = 534) plus best supportive care (BSC) or matching placebo (N = 266) plus BSC. Lonsurf dosing was based on BSA with a starting dose of 35 mg/m<sup>2</sup>/dose. Study treatment was administered orally twice daily after morning and evening meals for 5 days a week with 2-day rest for 2 weeks, followed by 14-day rest, repeated every 4 weeks. Patients continued therapy until disease progression or unacceptable toxicity (see section 4.2).</p><p>&nbsp;</p><p>Of the 800 randomised patients, the median age was 63 years, 61% were male, 58% were Caucasian/White, 35% were Asian/Oriental, and 1% were Black/African American, and all patients had baseline Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. The primary site of disease was colon (62%) or rectum (38%). KRAS status was wild (49%) or mutant (51%) at study entry. The median number of prior lines of therapy for metastatic disease was 3. All patients received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. All but 1 patient received bevacizumab, and all but 2 patients with KRAS wild type tumours received panitumumab or cetuximab. The 2 treatment groups were comparable with respect to demographic and baseline disease characteristics.</p><p>&nbsp;</p><p>An OS analysis of the study, carried out as planned at 72% (N = 574) of events, demonstrated a clinically meaningful and statistically significant survival benefit of Lonsurf plus BSC compared to placebo plus BSC (hazard ratio: 0.68; 95% confidence interval [CI] [0.58 to 0.81]; p &lt; 0.0001) and a median OS of 7.1 months vs 5.3 months, respectively; with 1-year survival rates of 26.6% and 17.6%, respectively. PFS was significantly improved in patients receiving Lonsurf plus BSC (hazard ratio: 0.48; 95% CI [0.41 to 0.57]; p &lt; 0.0001 (see Table 7, Figure 1 and Figure 2).</p><p>&nbsp;</p><p><strong>Table&nbsp;7 - Efficacy results from the </strong><strong>Phase III (RECOURSE) clinical study in patients with metastatic colorectal cancer</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Lonsurf plus BSC<br />(N=534)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo plus BSC<br />(N=266)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of deaths, N (%)</p></td><td style="vertical-align:bottom"><p>364 (68.2)</p></td><td style="vertical-align:bottom"><p>210 (78.9)</p></td></tr><tr><td style="vertical-align:top"><p>Median OS (months)<sup>a</sup> [95% CI]<sup>b</sup></p></td><td style="vertical-align:bottom"><p>7.1 [6.5, 7.8]</p></td><td style="vertical-align:bottom"><p>5.3 [4.6, 6.0]</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio [95% CI]</p></td><td colspan="2" style="vertical-align:bottom"><p>0.68 [0.58, 0.81]</p></td></tr><tr><td style="vertical-align:top"><p>P-value<sup>c</sup></p></td><td colspan="2" style="vertical-align:bottom"><p>&lt; 0.0001 (1-sided and 2-sided)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression-Free Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of progression or death, N&nbsp;(%)</p></td><td style="vertical-align:bottom"><p>472 (88.4)</p></td><td style="vertical-align:bottom"><p>251 (94.4)</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS (months)<sup>a</sup> [95% CI]<sup>b</sup></p></td><td style="vertical-align:bottom"><p>2.0 [1.9, 2.1]</p></td><td style="vertical-align:bottom"><p>1.7 [1.7, 1.8]</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio [95% CI]</p></td><td colspan="2" style="vertical-align:bottom"><p>0.48 [0.41, 0.57]</p></td></tr><tr><td style="vertical-align:top"><p>P-value<sup>c</sup></p></td><td colspan="2" style="vertical-align:bottom"><p>&lt;0.0001 (1-sided and 2-sided)</p></td></tr></tbody></table><p><sup>a</sup> Kaplan-Meier estimates</p><p><sup>b</sup> Methodology of Brookmeyer and Crowley</p><p><sup>c</sup> Stratified log-rank test (strata: KRAS status, time since diagnosis of first metastasis, region)</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Figure 1- Kaplan-Meier curves of overall survival</strong> <strong>in patients with metastatic colorectal cancer (RECOURSE)</strong></p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1058" style='position:absolute;left:0;text-align:left;
 margin-left:21.3pt;margin-top:13.35pt;width:411.05pt;height:225pt;z-index:251650048'
 coordorigin="1844,1894" coordsize="8221,4500">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="_x0000_s1059" type="#_x0000_t75" style='position:absolute;
  left:1845;top:1894;width:8220;height:4500'>
  <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title="Figure1_v2"/>
 </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
  path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1060" type="#_x0000_t202" style='position:absolute;
  left:4461;top:5518;width:3541;height:477;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1060'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:7.0pt'>Months from Randomisation</span><span
     lang=FR style='font-size:7.0pt;mso-ansi-language:FR'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1061" type="#_x0000_t202" style='position:absolute;
  left:8003;top:2141;width:927;height:387;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1061'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Placebo</span><span
     lang=FR style='font-size:7.0pt;mso-ansi-language:FR'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1062" type="#_x0000_t202" style='position:absolute;
  left:5065;top:2836;width:3504;height:818;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1062'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
     style='font-size:7.0pt'>Hazard ratio for death, 0.68 (95% CI, 0.58-0.81)<o:p></o:p></span></p>
     <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
     style='font-size:7.0pt'>P&lt;0.0001</span><span style='font-size:7.0pt;
     mso-ansi-language:EN-US'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1063" type="#_x0000_t202" style='position:absolute;
  left:2112;top:6002;width:782;height:380;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1063'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Placebo</span><span
     lang=FR style='font-size:7.0pt;mso-ansi-language:FR'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1064" type="#_x0000_t202" style='position:absolute;
  left:2040;top:1991;width:526;height:3467;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
   mso-next-textbox:#_x0000_s1064'>
   <![if RotText]><![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:7.0pt'>Survival Probability (%)</span><span
     lang=FR style='font-size:7.0pt;mso-ansi-language:FR'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]><![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1065" type="#_x0000_t202" style='position:absolute;
  left:8002;top:1958;width:928;height:405;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1065'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Lonsurf<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1066" type="#_x0000_t202" style='position:absolute;
  left:2112;top:5848;width:920;height:380;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1066'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Lonsurf<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1067" type="#_x0000_t202" style='position:absolute;
  left:1844;top:5660;width:1541;height:375;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1067'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>No. at Risk:<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="38" height="235" alt="Text Box: Survival Probability (%)" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><img width="550" height="301" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Figure 2 - Kaplan-Meier curves of progression-free survival</strong> <strong>in patients with metastatic colorectal cancer (RECOURSE)</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:group
 id="_x0000_s1048" style='position:absolute;left:0;text-align:left;
 margin-left:22.85pt;margin-top:.1pt;width:398.9pt;height:216.35pt;z-index:251649024'
 coordorigin="1875,8103" coordsize="7978,4327">
 <v:shape id="_x0000_s1049" type="#_x0000_t75" style='position:absolute;left:1918;
  top:8103;width:7935;height:4320'>
  <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
   o:title="Figure2"/>
 </v:shape><v:shape id="_x0000_s1050" type="#_x0000_t202" style='position:absolute;
  left:4406;top:9113;width:4247;height:1343;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1050'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
     style='font-size:7.0pt'>Hazard ratio for progression or death, 0.48 (95%
     CI, 0.41-0.57)<o:p></o:p></span></p>
     <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
     style='font-size:7.0pt'>P&lt;0.0001 by log-rank test<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1051" type="#_x0000_t202" style='position:absolute;
  left:7794;top:8196;width:1204;height:404;visibility:visible;
  mso-height-percent:200;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1051;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=FR style='font-size:7.0pt;mso-ansi-language:
     FR'>Lonsurf<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1052" type="#_x0000_t202" style='position:absolute;
  left:7777;top:8338;width:1390;height:379;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQAGxQqgLgIAAFQEAAAOAAAAZHJzL2Uyb0RvYy54bWysVMlu2zAQvRfoPxC811psx7ZgOUiduiiQ
LkDaS28USVlEuZWkLSVf3yHlOO52KaoDweEMH9+8mdH6elASHbnzwugaF5McI66pYULva/zl8+7V
EiMfiGZEGs1r/MA9vt68fLHubcVL0xnJuEMAon3V2xp3IdgqyzztuCJ+YizX4GyNUySA6fYZc6QH
dCWzMs+vst44Zp2h3Hs4vR2deJPw25bT8LFtPQ9I1hi4hbS6tDZxzTZrUu0dsZ2gJxrkH1goIjQ8
eoa6JYGggxO/QSlBnfGmDRNqVGbaVlCecoBsivyXbO47YnnKBcTx9iyT/3+w9MPxk0OC1XiaLzDS
REGRvkKpEOMo8CFwVEaReusriL23EB2G12aAYqeEvb0z9JtH2mw7ovf8xjnTd5wwIFnEm9nF1RHH
R5Cmf28YvEUOwSSgoXUqKgiaIECHYj2cCwQ8EIXDcrqYlVdzjCj4ilk+XS3n6Q1SPV23zoe33CgU
NzV20AEJnhzvfIh0SPUUEl/zRgq2E1Imw+2brXToSKBbduk7of8UJjXqa7yal/NRgb9C5On7E4QS
AdpeClXj5TmIVFG3N5qlpgxEyHEPlKU+CRm1G1UMQzOkwhWpi6PKjWEPIK0zY5vDWMKmM+4Rox5a
vMb++4E4jpF8p6E8q2I2izORjNl8UYLhLj3NpYdoClA1DhiN221Ic5SEszdQxp1IAj8zOXGG1k26
n8YszsalnaKefwabHwAAAP//AwBQSwMEFAAGAAgAAAAhAP0vMtbbAAAABQEAAA8AAABkcnMvZG93
bnJldi54bWxMj8FOwzAQRO9I/IO1SNyokxQVSONUVQTXSm2RuG7jbRKw1yF20vD3GC5wWWk0o5m3
xWa2Rkw0+M6xgnSRgCCune64UfB6fLl7BOEDskbjmBR8kYdNeX1VYK7dhfc0HUIjYgn7HBW0IfS5
lL5uyaJfuJ44emc3WAxRDo3UA15iuTUyS5KVtNhxXGixp6ql+uMwWgXjsdpO+yp7f5t2+n63ekaL
5lOp25t5uwYRaA5/YfjBj+hQRqaTG1l7YRTER8Lvjd7yYfkE4qQgy9IUZFnI//TlNwAAAP//AwBQ
SwECLQAUAAYACAAAACEAtoM4kv4AAADhAQAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlw
ZXNdLnhtbFBLAQItABQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAAAAAAAAAAAAAAC8BAABfcmVs
cy8ucmVsc1BLAQItABQABgAIAAAAIQAGxQqgLgIAAFQEAAAOAAAAAAAAAAAAAAAAAC4CAABkcnMv
ZTJvRG9jLnhtbFBLAQItABQABgAIAAAAIQD9LzLW2wAAAAUBAAAPAAAAAAAAAAAAAAAAAIgEAABk
cnMvZG93bnJldi54bWxQSwUGAAAAAAQABADzAAAAkAUAAAAA
" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1052'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Placebo<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1053" type="#_x0000_t202" style='position:absolute;
  left:3963;top:11625;width:3679;height:404;visibility:visible;
  mso-height-percent:200;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1053;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:7.0pt'>Months from Randomisation<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1054" type="#_x0000_t202" style='position:absolute;
  left:2078;top:12048;width:741;height:382;visibility:visible;
  mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1054'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Placebo<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1055" type="#_x0000_t202" style='position:absolute;
  left:2089;top:11913;width:803;height:404;visibility:visible;
  mso-height-percent:200;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1055;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Lonsurf<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1056" type="#_x0000_t202" style='position:absolute;
  left:1875;top:11754;width:1320;height:404;visibility:visible;
  mso-height-percent:200;mso-height-percent:200;mso-width-relative:margin;
  mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1056;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>No. at Risk:<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1057" type="#_x0000_t202" style='position:absolute;
  left:2064;top:8202;width:548;height:3558;visibility:visible;
  mso-width-percent:400;mso-width-percent:400;mso-width-relative:margin;
  mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
   mso-next-textbox:#_x0000_s1057;mso-fit-shape-to-text:t'>
   <![if RotText]><![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:7.0pt'>Progression-free Survival Probability
     (%)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]><![endif]></v:textbox>
 </v:shape></v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="40%" alt="Text Box: Progression-free Survival Probability (%)" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><img width="534" height="290" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>An updated OS analysis, carried out at 89% (N = 712) of events, confirmed the clinically meaningful and statistically significant survival benefit of Lonsurf plus BSC compared to placebo plus BSC (hazard ratio: 0.69; 95% CI [0.59 to 0.81]; p &lt; 0.0001) and a median OS of 7.2 months vs 5.2 months; with 1-year survival rates of 27.1% and 16.6%, respectively.</p><p>&nbsp;</p><p>The OS and PFS benefit was observed consistently, in all relevant pre-specified subgroups, including race, geographic region, age (&lt; 65; &ge; 65), sex, ECOG PS, KRAS status, time since diagnosis of first metastasis, number of metastatic sites, and primary tumour site. The Lonsurf survival benefit&nbsp; was maintained after adjusting for all significant prognostic factors, namely, time since diagnosis of first metastasis, ECOG PS and number of metastatic sites (hazard ratio: 0.69; 95% CI [0.58 to 0.81]).</p><p>&nbsp;</p><p>Sixty one percent (61%, N = 485) of all randomised patients received a fluoropyrimidine as part of their last treatment regimen prior to randomisation, of which 455 (94%) were refractory to the fluoropyrimidine at that time. Among these patients, the OS benefit with Lonsurf was maintained (hazard ratio: 0.75, 95% CI [0.59 to 0.94]).</p><p>&nbsp;</p><p>Eighteen percent (18%, N = 144) of all randomised patients received regorafenib prior to randomisation. Among these patients, the OS benefit with Lonsurf was maintained (hazard ratio: 0.69, 95% CI [0.45 to 1.05]). The effect was also maintained in regorafenib-naive patients (hazard ratio: 0.69, 95% CI [0.57 to 0.83]).</p><p>&nbsp;</p><p>The DCR (complete response or partial response or stable disease) was significantly higher in patients treated with Lonsurf (44% vs 16%, p &lt; 0.0001).</p><p>&nbsp;</p><p>Treatment with Lonsurf plus BSC resulted in a statistically significant prolongation of PS &lt;2 in comparison to placebo plus BSC. The median time to PS &ge; 2 for the Lonsurf group and placebo group was 5.7 months and 4.0 months, respectively, with a hazard ratio &nbsp;of 0.66 (95% CI: [0.56, 0.78]), p&nbsp;&lt;&nbsp;0.0001.</p><p>&nbsp;</p><p><em><u>Randomised phase III study of Lonsurf in combination with bevacizumab versus Lonsurf </u></em>&nbsp;</p><p>&nbsp;</p><p><u>The clinical efficacy and safety of Lonsurf in combination with bevacizumab, versus Lonsurf monotherapy, were evaluated in an international, randomised, open-label, phase III study (SUNLIGHT) in patients with metastatic colorectal cancer who had been previously treated with a maximum of two prior systemic treatment regimens for advanced disease, including a fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody and/or an anti-EGFR monoclonal antibody for patients with a RAS wild type tumour. The primary efficacy endpoint was overall survival (OS) and the key secondary efficacy endpoint was progression-free survival (PFS).&nbsp;</u>&nbsp;</p><p>&nbsp;</p><p><u>In total, 492 patients were randomised (1:1) to receive Lonsurf with bevacizumab (N = 246) or Lonsurf monotherapy (N = 246).&nbsp;</u>&nbsp;</p><p><u>Patients received Lonsurf (starting dose of 35 mg/m</u><u><sup>2</sup></u><u>) administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle alone or combined with bevacizumab (5 mg/kg) administered intravenously every 2 weeks (on days 1 and 15) of each 4-week cycle. Patients continued therapy until disease progression or unacceptable toxicity (see section 4.2). Bevacizumab monotherapy was not allowed.&nbsp;</u>&nbsp;</p><p><u>Baseline characteristics were generally balanced between the two groups. The median age was 63 years (range: 20-90), with 44% &ge; 65 years of age and 12% &ge; 75 years of age, 52% of patients were male and 95% were white, 46% had ECOG PS 0 and 54% had ECOG PS 1. The primary site of disease was colon (73%) or rectum (27%). Overall, 71% of the patients had a RAS mutant tumour. The median duration of treatment was 5 months in the Lonsurf-bevacizumab group and 2 months in the Lonsurf group. A total of 92% of patients received two prior anticancer treatment regimens for advanced CRC, 5% received one and 3% received more than two. All patients received prior fluoropyrimidine, irinotecan and oxaliplatin, 72% received prior anti-VEGF monoclonal antibody,</u><s> </s><u>94% of patients with a RAS wild type tumour received prior anti-EGFR monoclonal antibody.</u>&nbsp;</p><p>&nbsp;</p><p><u>Lonsurf in combination with bevacizumab resulted in a statistically significant improvement in OS and PFS compared to Lonsurf monotherapy (see Table 8 and Figures 3 and 4).</u>&nbsp;</p><p><br /><strong><u>Table 8 - Efficacy results from the Phase III (SUNLIGHT) clinical study in patients with metastatic colorectal cancer&nbsp;</u></strong>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong><u>Lonsurf plus bevacizumab</u></strong>&nbsp;<br /><strong><u>(N=</u></strong><strong><u>246</u></strong><strong><u>)</u></strong>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong><u>Lonsurf</u></strong>&nbsp;<br /><strong><u>(N=246)</u></strong>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><u>Overall survival</u></strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Number of deaths, N (%)</u>&nbsp;</p></td><td style="vertical-align:bottom"><p><u>148 (60.2)</u>&nbsp;</p></td><td style="vertical-align:bottom"><p><u>183 (74.4)</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Median OS (months)</u><u><sup>a</sup></u><u> [95% CI]</u><u><sup>b</sup></u>&nbsp;</p></td><td style="vertical-align:bottom"><p><u>10.8 [9.4, 11.8]</u>&nbsp;</p></td><td style="vertical-align:bottom"><p><u>7.5 [6.3, 8.6]</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Hazard ratio [95% CI]</u>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><u>0.61 [0.49, 0.77]</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>P-value</u><u><sup>c</sup></u>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><u>&lt; </u><s> </s><u>0.001 (1-sided)</u>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><u>Progression-free survival (per investigator)</u></strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Number of progression or death, N (%)</u>&nbsp;</p></td><td style="vertical-align:bottom"><p><u>206 (83.7)</u>&nbsp;</p></td><td style="vertical-align:bottom"><p><u>236 (95.9)</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Median PFS (months)</u><u><sup>a</sup></u><u> [95% CI]</u><u><sup>b</sup></u>&nbsp;</p></td><td style="vertical-align:bottom"><p><u>5.6 [4.5, 5.9]</u>&nbsp;</p></td><td style="vertical-align:bottom"><p><u>2.4 [2.1, 3.2]</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Hazard ratio [95% CI]</u>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><u>0.44 [0.36, 0.54]</u>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>P-value</u><u><sup>c</sup></u>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><u>&lt; 0.001 (1-sided)</u>&nbsp;</p></td></tr></tbody></table><p><u><sup>a</sup></u><u>&nbsp; </u><u>Kaplan-Meier estimates</u>&nbsp;</p><p><u><sup>b</sup></u><u>&nbsp; </u><u>Methodology of Brookmeyer and Crowley</u>&nbsp;</p><p><u><sup>c</sup></u><u>&nbsp; </u><u>Stratified log-rank test (strata: region, time since first metastasis diagnosis, RAS status)</u>&nbsp;</p><p>&nbsp;</p><p><strong>Figure 3- Kaplan-Meier curves of overall survival in patients with metastatic colorectal cancer (SUNLIGHT)</strong></p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1074" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:12.15pt;margin-top:258.65pt;width:87.6pt;height:19.35pt;
 z-index:251660288;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1074'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Lonsurf+bevacizumab</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1070" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:363.75pt;
 margin-top:12.1pt;width:88.65pt;height:19.3pt;z-index:251656192;visibility:visible;
 mso-width-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1070'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Lonsurf</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Zone_x0020_de_x0020_texte_x0020_2"
 o:spid="_x0000_s1068" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:38.55pt;margin-top:.8pt;width:89.75pt;height:19.3pt;
 z-index:251654144;visibility:visible;mso-position-horizontal:right;
 mso-position-horizontal-relative:margin;mso-width-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#Zone_x0020_de_x0020_texte_x0020_2'/>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Lonsurf+bevacizumab</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1072" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:200.4pt;
 margin-top:235.6pt;width:190.75pt;height:26.85pt;z-index:251658240;
 visibility:visible;mso-width-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1072'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>OS (months from randomization)</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1073" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:80.55pt;
 margin-top:251.2pt;width:120.9pt;height:19.35pt;z-index:251659264;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1073'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Number of patients at risk</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1075" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:22.55pt;
 margin-top:269.45pt;width:67.15pt;height:19.35pt;z-index:251661312;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1075'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Lonsurf</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1071" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:-33.55pt;
 margin-top:104.25pt;width:149.75pt;height:31.05pt;rotation:-90;z-index:251657216;
 visibility:visible;mso-width-relative:margin' filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1071'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt;color:#0070C0'>Survival
    probability (%)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--><img width="44" height="203" alt="Text Box: Survival probability (%)" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if gte vml 1]><v:shape
 id="_x0000_s1069" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:260.1pt;margin-top:31.45pt;width:183.35pt;
 height:66.65pt;z-index:251655168;visibility:visible;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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=
" stroked="f">
 <v:fill opacity="0"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
    style='font-size:7.0pt;color:#0070C0'>Hazard ratio for death, 0.61 (95% CI,
    0.49-0.77)<o:p></o:p></span></p>
    <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
    style='font-size:7.0pt;color:#0070C0'>P&lt;0.001 (1-sided)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--><img width="247" height="92" alt="Text Box: Hazard ratio for death, 0.61 (95% CI, 0.49-0.77)
P&lt;0.001 (1-sided)
" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /><strong><!--[if gte vml 1]><v:shape
 id="Image_x0020_192" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:454pt;
 height:295pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image009.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="393" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image010.jpg" /></strong></p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><strong>Figure 4 - Kaplan-Meier curves of progression-free survival in patients with metastatic colorectal cancer (SUNLIGHT)</strong></p><p><!--[if gte vml 1]><v:group
 id="Groupe_x0020_5" o:spid="_x0000_s1077" style='position:absolute;left:0;
 text-align:left;margin-left:3.25pt;margin-top:1.3pt;width:450.25pt;height:277.8pt;
 z-index:251663360' coordsize="57180,35279" o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQBmCnuU5QMAAC4RAAAOAAAAZHJzL2Uyb0RvYy54bWzUWF1zozYUfe9M/4NG744lgTAwITubZJ2X
tN2Z7b7smwwyMAVEJSU47fS/90qAPzadabvZbmM/2CD0ce/ROecKX77ZtQ16lNrUqsswvSAYyS5X
Rd2VGf7483oRY2Ss6ArRqE5m+Eka/Obq++8uhz6VTFWqKaRGMEln0qHPcGVtny6XJq9kK8yF6mUH
D7dKt8LCrS6XhRYDzN42S0ZItByULnqtcmkMtN6OD/GVn3+7lbn9abs10qImwxCb9d/af2/c9/Lq
UqSlFn1V51MY4guiaEXdwaL7qW6FFehB18+mautcK6O29iJX7VJtt3UufQ6QDSWfZXOn1UPvcynT
oez3MAG0n+H0xdPmPz6+16guMswx6kQLW+RXlYg7bIa+TKHLne4/9O/11FCOdy7d3Va37hcSQTuP
6tMeVbmzKIdGvqIxoQFGOTwLOFslLBxxzyvYnGfj8urd34xczgsvXXz7cIYeOGQOMJmXwfShEr30
6BuHwQQTm2H6BHxGhUQW8pSIjWj5ng4qZHfXCpKnnhWmv1f5LwZ16qYSXSnfaq2GSooCQqRuJCSy
H+pQN6lxk2yGH1QBWyIerPITObyRVkBjGgH94eObJ/gXUcKSECIEoGkQUkYngs9bwQJKGA+nrUiC
FYx3q894irTXxt5J1SJ3kWENAvIriMd7Y8eucxe3751a100D7SJtOjRkOOGM+wFHT9ragsabus1w
PMbsB7j833WFv7aibsZriKXpJkAcBiMadrfZeZaGwQz0RhVPAJEHA5QNHgTxVkr/htEAes6w+fVB
aImR6HJozrCdL2+sNwCXzUSZcZH/nDs02Yvsf2PPkVrDiAJdQJjPNUsp4WQFsDrNMh7x8IVEMaqp
C8cVt77R5eam0ehRgCuv/WckWdNXYmydl5u6eo6ezOFIcsS/iTYiBaoDU90zR3pvwb8nlIXkmiWL
dRSvFuE65ItkReIFocl1EpEwCW/Xf7gIaJhWdVHI7r4GcY9VCRr/mY9MhWk0cl8QTgRxEv0JAl4T
+4SPgfqXyjkJ30MGGMy/HhVP+L+SlXdkp4YXywo99LouKxDj7H1vwb3WtXePwwrfXHyMANPHCvca
xMfAv8F/vfgCQiPKfcEdaevKJgtIwONJgkFIksh3OCevno4QX4FU396rGYEy+Xrokqx4TCEid4Si
PAn5ytXBA1soh5MVmPRo2CGPgvjcKnt0xpWdkVdV2SdbYTFjsYf1iCgUjoVJdM5E8dQ/VJIzOwIC
9K/HVsKIRJQm4xsDJxQO76e2QgISkrNmi/fBr88W/+oJL+X+eDX9geDe+o/v/Rnn8DfH1Z8AAAD/
/wMAUEsDBBQABgAIAAAAIQCVca1a3gAAAAcBAAAPAAAAZHJzL2Rvd25yZXYueG1sTI9BS8NAFITv
gv9heYI3u0kkscZsSinqqQhtBfG2zb4modm3IbtN0n/v86THYYaZb4rVbDsx4uBbRwriRQQCqXKm
pVrB5+HtYQnCB01Gd45QwRU9rMrbm0Lnxk20w3EfasEl5HOtoAmhz6X0VYNW+4Xrkdg7ucHqwHKo
pRn0xOW2k0kUZdLqlnih0T1uGqzO+4tV8D7paf0Yv47b82lz/T6kH1/bGJW6v5vXLyACzuEvDL/4
jA4lMx3dhYwXnYIs5aCCJAPB7nP0xM+OCtJ0mYAsC/mfv/wBAAD//wMAUEsBAi0AFAAGAAgAAAAh
ALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAU
AAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAAAAAAAAAAAAAvAQAAX3JlbHMvLnJlbHNQSwECLQAU
AAYACAAAACEAZgp7lOUDAAAuEQAADgAAAAAAAAAAAAAAAAAuAgAAZHJzL2Uyb0RvYy54bWxQSwEC
LQAUAAYACAAAACEAlXGtWt4AAAAHAQAADwAAAAAAAAAAAAAAAAA/BgAAZHJzL2Rvd25yZXYueG1s
UEsFBgAAAAAEAAQA8wAAAEoHAAAAAA==
">
 <v:shape id="_x0000_s1078" type="#_x0000_t202" style='position:absolute;
  left:-6929;top:13411;width:23102;height:3937;rotation:-90;visibility:visible'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1078'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt;color:#0070C0'>Progression-free
     Survival probability (%)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1079" type="#_x0000_t202" style='position:absolute;
  left:46129;width:11051;height:2565;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f">
  <v:fill opacity="0"/>
  <v:textbox style='mso-next-textbox:#_x0000_s1079;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=FR style='font-size:7.0pt;color:#0070C0;
     mso-ansi-language:FR'>Lonsurf</span><span lang=EN-GB style='font-size:
     7.0pt;color:#0070C0'>+bevacizumab</span><span lang=FR style='font-size:
     7.0pt;color:#0070C0;mso-ansi-language:FR'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1080" type="#_x0000_t202" style='position:absolute;
  left:26203;top:30161;width:23036;height:3410;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1080'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt;color:#0070C0'>PFS
     (months from randomization)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1081" type="#_x0000_t202" style='position:absolute;
  left:9758;top:31594;width:15352;height:2456;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1081'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt;color:#0070C0'>Number
     of patients at risk<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1082" type="#_x0000_t202" style='position:absolute;
  top:32822;width:11121;height:2457;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1082'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
     style='font-size:7.0pt;color:#0070C0'>Lonsurf+bevacizumab<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1083" type="#_x0000_t202" style='position:absolute;
  left:46061;top:1501;width:10304;height:2456;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1083'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt;color:#0070C0'>Lonsurf<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><![endif]--><img width="603" height="374" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image011.gif" /><!--[if gte vml 1]><v:shape
 id="_x0000_s1084" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:22.5pt;margin-top:269.8pt;width:67.15pt;height:19.35pt;
 z-index:251664384;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQBS2ZsL8AEAALIDAAAOAAAAZHJzL2Uyb0RvYy54bWysU02P0zAQvSPxHyzfadKwrbZR0xXsslyW
D2nhwm1qO41F7DG226T8esZOWyq4IXKwHI/nzbw3z+u70fTsoHzQaBs+n5WcKStQartr+Ncvj69u
OQsRrIQerWr4UQV+t3n5Yj24WlXYYS+VZwRiQz24hncxurooguiUgTBDpywFW/QGIv36XSE9DIRu
+qIqy2UxoJfOo1Ah0OnDFOSbjN+2SsRPbRtUZH3DqbeYV5/XbVqLzRrqnQfXaXFqA/6hCwPaUtEL
1ANEYHuv/4IyWngM2MaZQFNg22qhMgdiMy//YPPcgVOZC4kT3EWm8P9gxcfDZ8+0bHhVLjmzYGhI
32hUTCoW1RgVq5JIgws13X12dDuOb3GkYWfCwT2h+B6YxfsO7E698R6HToGkJucps7hKnXBCAtkO
H1BSLdhHzEBj601SkDRhhE7DOl4GRH0wQYe3i2o1n3MmKFTdLJavb3MFqM/Jzof4XqFhadNwT/PP
4HB4CjE1A/X5Sqpl8VH3ffZAb9nQ8NWiWuSEq4jRkSzaa0P1y/RNpkkc31mZkyPoftpTgd6eSCee
E+M4bscs8s3qLOYW5ZFk8DhZkp4QbTr0PzkbyI4NDz/24BVnYAUdNzyet/cx+/csLRkj8zqZODnv
+j/38vupbX4BAAD//wMAUEsDBBQABgAIAAAAIQCPX1Xv3wAAAAoBAAAPAAAAZHJzL2Rvd25yZXYu
eG1sTI/BTsMwEETvSPyDtUjcqA1p2ibEqRCIK6gFKvW2jbdJRLyOYrcJf497guPsjGbfFOvJduJM
g28da7ifKRDElTMt1xo+P17vViB8QDbYOSYNP+RhXV5fFZgbN/KGzttQi1jCPkcNTQh9LqWvGrLo
Z64njt7RDRZDlEMtzYBjLLedfFBqIS22HD802NNzQ9X39mQ1fL0d97u5eq9fbNqPblKSbSa1vr2Z
nh5BBJrCXxgu+BEdysh0cCc2XnQa5mmcEjSkSbYAcQksswTEIV6WqwRkWcj/E8pfAAAA//8DAFBL
AQItABQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBl
c10ueG1sUEsBAi0AFAAGAAgAAAAhADj9If/WAAAAlAEAAAsAAAAAAAAAAAAAAAAALwEAAF9yZWxz
Ly5yZWxzUEsBAi0AFAAGAAgAAAAhAFLZmwvwAQAAsgMAAA4AAAAAAAAAAAAAAAAALgIAAGRycy9l
Mm9Eb2MueG1sUEsBAi0AFAAGAAgAAAAhAI9fVe/fAAAACgEAAA8AAAAAAAAAAAAAAAAASgQAAGRy
cy9kb3ducmV2LnhtbFBLBQYAAAAABAAEAPMAAABWBQAAAAA=
" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1084'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Lonsurf</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1076" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:209.05pt;
 margin-top:46.4pt;width:212.35pt;height:79.5pt;z-index:251662336;visibility:visible;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
 <v:fill opacity="0"/>
 <v:textbox style='mso-next-textbox:#_x0000_s1076'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
    style='font-size:7.0pt;color:#0070C0'>Hazard ratio for progression or
    death, 0.44 (95% CI, 0.36-0.54)<o:p></o:p></span></p>
    <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
    style='font-size:7.0pt;color:#0070C0'>P&lt;0.001 (1-sided)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--><img width="286" height="109" alt="Text Box: Hazard ratio for progression or death, 0.44 (95% CI, 0.36-0.54)
P&lt;0.001 (1-sided)
" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image012.gif" /><strong><!--[if gte vml 1]><v:shape
 id="Image_x0020_1" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:454pt;
 height:295pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image013.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="393" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image014.jpg" /></strong><br />&nbsp;</p><p>&nbsp;</p><p><u>The OS and PFS benefit was observed consistently, in all randomization strata and pre specified subgroups, including gender, age (&lt; 65, &ge; 65 years), location of primary disease (right, left), ECOG performance status (0, &ge;1),&nbsp;</u><s> </s><u>prior surgical resection, number of metastatic sites (1-2, &ge; 3), neutrophils to lymphocytes ratio (NLR &lt; 3, NLR &ge; 3), number of prior metastatic drug regimens (1, &ge; 2), BRAF status, MSI status, prior bevacizumab and subsequent regorafenib.</u>&nbsp;</p><p>&nbsp;</p><p><em>Metastatic gastric cancer</em></p><p>The clinical efficacy and safety of Lonsurf were evaluated in an international, randomised, double-blind, placebo-controlled Phase III study (TAGS) in patients with previously treated metastatic gastric cancer (including adenocarcinoma of the gastroesophageal junction), who had been previously treated with at least two prior systemic treatment regimens for advanced disease, including fluoropyrimidine-, platinum-, and either taxane- or irinotecan-based chemotherapy, plus if appropriate human epidermal growth factor receptor 2 (HER2) -targeted therapy. The primary efficacy endpoint was overall survival (OS), and supportive efficacy endpoints were progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), time to deterioration of ECOG performance status &ge;2 and quality of life (QoL). Tumour assessments, according to the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, were performed by the investigator/local radiologist every 8 weeks.</p><p>&nbsp;</p><p>In total, 507 patients were randomised 2:1 to receive Lonsurf (N = 337) plus best supportive care (BSC) or&nbsp; placebo (N = 170) plus BSC. Lonsurf dosing was based on BSA with a starting dose of 35 mg/m2/dose. Study treatment was administered orally twice daily after morning and evening meals for 5 days a week with 2-day rest for 2 weeks, followed by 14-day rest, repeated every 4 weeks. Patients continued therapy until disease progression or unacceptable toxicity (see section 4.2).</p><p>&nbsp;</p><p>Of the 507 randomised patients, the median age was 63 years, 73% were male, 70% were White, 16% were Asian, and &lt;1% were Black/African American, and all patients had baseline Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. Primary cancer was gastric (71.0%) or gastroesophageal junction cancer (28.6%) or both (0.4%). The median number of prior regimens of therapy for metastatic disease was 3. Nearly all (99.8%) patients received prior fluoropyrimidine, 100% received prior platinum therapy and 90.5% received prior taxane therapy. Approximately half (55.4%) of patients received prior irinotecan, 33.3% received prior ramucirumab, and 16.6% received prior HER2-targeted therapy. The 2 treatment groups were comparable with respect to demographic and baseline disease characteristics.</p><p>&nbsp;</p><p>An OS analysis of the study, carried out as planned at 76% (N = 384) of events, demonstrated that Lonsurf plus BSC resulted in a statistically significant improvement in OS compared to placebo plus BSC with an hazard ratio (HR) of 0.69 (95% CI: 0.56, 0.85; 1- and 2-sided p-values were 0.0003 and 0.0006, respectively) corresponding to a 31% reduction in the risk of death in the Lonsurf group. The median OS was 5.7 months (95% CI: 4.8, 6.2) for the Lonsurf group versus 3.6 months (95% CI: 3.1, 4.1) for the placebo group; with 1-year survival rates of 21.2% and 13.0%, respectively.</p><p>PFS was significantly improved in patients receiving Lonsurf plus BSC compared to placebo plus BSC (HR of 0.57; 95% CI [0.47 to 0.70]; p &lt; 0.0001 (see Table 9, Figure 5 and Figure 6).</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 9 - Efficacy results from the Phase III (TAGS) clinical study in patients with metastatic gastric cancer</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Lonsurf plus BSC<br />(N=337)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo plus BSC<br />(N=170)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of deaths, N (%)</p></td><td style="vertical-align:top"><p>244 (72.4)</p></td><td style="vertical-align:top"><p>140 (82.4)</p></td></tr><tr><td style="vertical-align:top"><p>Median OS (months)<sup>a</sup> [95% CI]<sup>b</sup></p></td><td style="vertical-align:top"><p>5.7 [4.8, 6.2]</p></td><td style="vertical-align:top"><p>3.6 [3.1, 4.1]</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio [95% CI]</p></td><td colspan="2" style="vertical-align:bottom"><p>0.69 [0.56, 0.85]</p></td></tr><tr><td style="vertical-align:top"><p>P-value<sup>c</sup></p></td><td colspan="2" style="vertical-align:bottom"><p>0.0003 (1-sided), 0.0006 (2-sided)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression-Free Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of progression or death, N&nbsp;(%)</p></td><td style="vertical-align:top"><p>287 (85.2)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>156 (91.8)</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS (months)<sup>a</sup> [95% CI]<sup>b</sup></p></td><td style="vertical-align:top"><p>2.0 [1.9, 2.3]</p></td><td style="vertical-align:top"><p>1.8 [1.7, 1.9]</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio [95% CI]</p></td><td colspan="2" style="vertical-align:bottom"><p>0.57 [0.47, 0.70]</p></td></tr><tr><td style="vertical-align:top"><p>P-value<sup>c</sup></p></td><td colspan="2" style="vertical-align:bottom"><p>&lt;0.0001 (1-sided and 2-sided)</p></td></tr></tbody></table><p><sup>a</sup> Kaplan-Meier estimates</p><p><sup>b</sup> Methodology of Brookmeyer and Crowley</p><p><sup>c</sup> Stratified log-rank test (strata: region, ECOG status at baseline, prior&nbsp; ramucirumab treatment)</p><p>&nbsp;</p><p>Figure 5- Kaplan-Meier curves of overall survival in patients with metastatic gastric cancer (TAGS)</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE<span style='mso-spacerun:yes'> 
</span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_23" o:spid="_x0000_s1037" style='width:397.15pt;height:232.3pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordorigin="1844,1762" coordsize="7943,4646" o:gfxdata="UEsDBBQABgAIAAAAIQCKFT+YDAEAABUCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRwU7DMAyG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">
 <v:shape id="Picture_x0020_24" o:spid="_x0000_s1038" type="#_x0000_t75" alt="Image1"
  style='position:absolute;left:2397;top:1857;width:7390;height:4551;
  visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image015.jpg"
   o:title="Image1"/>
 </v:shape><v:group id="Group_x0020_25" o:spid="_x0000_s1039" style='position:absolute;
  left:1844;top:1762;width:7730;height:4620' coordorigin="1844,1762"
  coordsize="7730,4620" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shape id="_x0000_s1040" type="#_x0000_t202" style='position:absolute;
   left:4461;top:5518;width:3541;height:477;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><span
      lang=EN-GB style='font-size:7.0pt'>Months from Randomisation</span><span
      lang=FR style='font-size:7.0pt;mso-ansi-language:FR'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1041" type="#_x0000_t202" style='position:absolute;
   left:8647;top:1931;width:927;height:387;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Placebo</span><span
      lang=FR style='font-size:7.0pt;mso-ansi-language:FR'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1042" type="#_x0000_t202" style='position:absolute;
   left:5051;top:2836;width:3504;height:818;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" stroked="f">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
      style='font-size:7.0pt'>Hazard ratio for death, 0.69 (95% CI, 0.56-0.85)</span><span
      style='font-size:7.0pt;mso-ansi-language:EN-US'><o:p></o:p></span></p>
      <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
      style='font-size:7.0pt'>P=0.0003 (1-sided) ; p =0.0006 (2-sided)</span><span
      style='font-size:7.0pt;mso-ansi-language:EN-US'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1043" type="#_x0000_t202" style='position:absolute;
   left:2112;top:6002;width:782;height:380;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Placebo</span><span
      lang=FR style='font-size:7.0pt;mso-ansi-language:FR'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1044" type="#_x0000_t202" style='position:absolute;
   left:2040;top:1991;width:526;height:3467;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'>
    <![if RotText]><![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><span
      lang=EN-GB style='font-size:7.0pt'>Survival Probability (%)</span><span
      lang=FR style='font-size:7.0pt;mso-ansi-language:FR'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]><![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1045" type="#_x0000_t202" style='position:absolute;
   left:8646;top:1762;width:928;height:405;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDUdfmVxAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NasJA
FIX3Bd9huEI3pU6aRQkxo5SgUKEWGnV/k7lNYjN3QmaM8e07hYLLw/n5ONl6Mp0YaXCtZQUviwgE
cWV1y7WC42H7nIBwHlljZ5kU3MjBejV7yDDV9spfNBa+FmGEXYoKGu/7VEpXNWTQLWxPHLxvOxj0
QQ611ANew7jpZBxFr9Jgy4HQYE95Q9VPcTGBu5mS/lR+5Odd8VSe409u9wkr9Tif3pYgPE3+Hv5v
v2sFcQx/X8IPkKtfAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhANR1+ZXEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Lonsurf<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1046" type="#_x0000_t202" style='position:absolute;
   left:2112;top:5848;width:920;height:380;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Lonsurf<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1047" type="#_x0000_t202" style='position:absolute;
   left:1844;top:5660;width:1541;height:375;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>No. at Risk:<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="38" height="234" alt="Text Box: Survival Probability (%)" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image016.gif" /><img width="531" height="311" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image017.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:397.15pt;height:232.3pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Figure 6 - Kaplan-Meier curves of progression-free survival in patients with metastatic gastric cancer (TAGS)</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE<span style='mso-spacerun:yes'> 
</span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Groupe_x0020_1" o:spid="_x0000_s1026" style='width:428.65pt;height:210.3pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordorigin="1882,7978" coordsize="8573,4206" o:gfxdata="UEsDBBQABgAIAAAAIQCKFT+YDAEAABUCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRwU7DMAyG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">
 <v:shape id="Picture_x0020_3" o:spid="_x0000_s1027" type="#_x0000_t75" alt="Image6"
  style='position:absolute;left:2262;top:8106;width:8132;height:4078;
  visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image018.jpg"
   o:title="Image6"/>
 </v:shape><v:group id="Group_x0020_4" o:spid="_x0000_s1028" style='position:absolute;
  left:1882;top:7978;width:8573;height:4199' coordorigin="1882,7978"
  coordsize="8573,4199" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:shape id="_x0000_s1029" type="#_x0000_t202" style='position:absolute;
   left:4506;top:11365;width:3679;height:404;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><span
      lang=EN-GB style='font-size:7.0pt'>Months from Randomisation<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1030" type="#_x0000_t202" style='position:absolute;
   left:5008;top:8776;width:4247;height:1343;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='line-height:normal'><span style='font-size:
      7.0pt;mso-ansi-language:EN-US'>Hazard ratio for progression or death,
      0.57 (95% CI, 0.47-0.70)<o:p></o:p></span></p>
      <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
      style='font-size:7.0pt'>P&lt;0.0001 (1-sided and 2-sided)<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1031" type="#_x0000_t202" style='position:absolute;
   left:9074;top:7978;width:1204;height:404;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=FR style='font-size:7.0pt;mso-ansi-language:
      FR'>Lonsurf<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1032" type="#_x0000_t202" style='position:absolute;
   left:9065;top:8127;width:1390;height:379;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBROa1cwwAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9fa8Iw
FMXfBb9DuMJehk3ng9TOKEM22GATrPp+29y1dc1NSTKt334RBj4ezp8fZ7keTCfO5HxrWcFTkoIg
rqxuuVZw2L9NMxA+IGvsLJOCK3lYr8ajJebaXnhH5yLUIo6wz1FBE0KfS+mrhgz6xPbE0fu2zmCI
0tVSO7zEcdPJWZrOpcGWI6HBnjYNVT/Fr4nc1yHrj+Xn5vRRPJan2Zbbr4yVepgML88gAg3hHv5v
v2sFC7hdiTdArv4AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAUTmtXMMAAADaAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Placebo<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1033" type="#_x0000_t202" style='position:absolute;
   left:2078;top:11795;width:741;height:382;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCFhwjEwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Na8JA
EIbvBf/DMkIvRTf1ICG6iohChVZoWu9jdkyi2dmQXTX9985B6G2GeT+emS9716gbdaH2bOB9nIAi
LrytuTTw+7MdpaBCRLbYeCYDfxRguRi8zDGz/s7fdMtjqSSEQ4YGqhjbTOtQVOQwjH1LLLeT7xxG
WbtS2w7vEu4aPUmSqXZYszRU2NK6ouKSX530bvq0PRw/1+dd/nY8T/Zcf6VszOuwX81ARerjv/jp
/rCCL/TyiwygFw8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAhYcIxMMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Placebo<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1034" type="#_x0000_t202" style='position:absolute;
   left:2129;top:8046;width:548;height:3558;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
    mso-fit-shape-to-text:t'>
    <![if RotText]><![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><span
      lang=EN-GB style='font-size:7.0pt'>Progression-free Survival Probability
      (%)<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]><![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1035" type="#_x0000_t202" style='position:absolute;
   left:2100;top:11668;width:803;height:404;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>Lonsurf<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1036" type="#_x0000_t202" style='position:absolute;
   left:1882;top:11513;width:1320;height:404;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f">
   <v:fill opacity="0"/>
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:7.0pt'>No. at Risk:<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="39" height="241" alt="Text Box: Progression-free Survival Probability (%)" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image019.gif" /><img width="575" height="283" src="file:///C:/Users/HNHZ_SA1/AppData/Local/Temp/msohtmlclip1/01/clip_image020.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:428.65pt;height:210.3pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>The OS and PFS benefit was observed consistently, in all randomization strata and across most pre-specified subgroups, including sex, age (&lt; 65; &ge; 65 years), ethnic origin, ECOG PS, prior ramucirumab treatment, prior irinotecan treatment, number of prior regimens (2; 3; &ge; 4), previous gastrectomy, primary tumour site (gastric; gastroesophageal junction) and HER2 status.</p><p>The ORR (complete response + partial response) was not significantly higher in patients treated with Lonsurf (4.5% vs 2.1 %, p-value = 0.2833) but the DCR (complete response or partial response or stable disease) was significantly higher in patients treated with Lonsurf (44.1% vs 14.5%, p &lt; 0.0001).</p><p>The median time to deterioration of ECOG performance status to &ge;2 was 4.3 months for the Lonsurf group versus 2.3 months for the placebo group with HR of 0.69 (95% CI: 0.562, 0.854), p value = 0.0005.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Lonsurf in all subsets of the paediatric population in refractory metastatic colorectal cancer and in refractory metastatic gastric cancer (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>There is limited data in Lonsurf treated patients aged 75 years and above:</p><p>87 patients (10%) in pooled data of the RECOURSE and TAGS studies, of which 2 patients were 85 years or older. The effect of Lonsurf on overall survival was similar in patients &lt;65 years and &ge;65 years of age.</p><p><u>- 58 patients (12%) were aged 75 years and above, of which 1 patient was 85 years or older in the SUNLIGHT study. The effect of Lonsurf in combination with bevacizumab on overall survival was similar in patients &lt; 65 years and &ge; 65 years of age.</u>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>After oral administration of Lonsurf with [<sup>14</sup>C]-trifluridine, at least 57% of the administered trifluridine was absorbed and only 3% of the dose was excreted into faeces. After oral administration of Lonsurf with [<sup>14</sup>C]-tipiracil hydrochloride, at least 27% of the administered tipiracil hydrochloride was absorbed and 50% of the total radioactivity dose measured into faeces, suggestive of moderate gastrointestinal absorption of tipiracil hydrochloride.</p><p>Following a single dose of Lonsurf (35 mg/m<sup>2</sup>) in patients with advanced solid tumours, the mean times to peak plasma concentrations (t<sub>max</sub>) of trifluridine and tipiracil hydrochloride were around 2 hours and 3 hours, respectively.</p><p>&nbsp;</p><p>In the pharmacokinetic (PK) analyses of the multiple dose administration of Lonsurf (35 mg/m<sup>2</sup>/dose, twice daily for 5 days a week with 2-day rest for 2 weeks followed by a 14-day rest, repeated every 4 weeks), trifluridine area under the concentration-time curve from time 0 to the last measurable concentration (AUC<sub>0-last</sub>) was approximately 3-fold higher and maximum concentration (C<sub>max)</sub> was approximately 2-fold higher after multiple dose administration (Day 12 of Cycle 1) of Lonsurf than after single-dose (Day 1 of Cycle 1).</p><p><u>&nbsp;</u></p><p>However, there was no accumulation for tipiracil hydrochloride, and no further accumulation of trifluridine with successive cycles (Day 12 of Cycles 2 and 3) of administration of Lonsurf.&nbsp; Following multiple doses of Lonsurf (35 mg/m<sup>2</sup>/dose twice daily) in patients with advanced solid tumours, the mean times to peak plasma concentrations (t<sub>max</sub>) of trifluridine and tipiracil hydrochloride were around 2 hours and 3 hours, respectively.</p><p>&nbsp;</p><p><em>Contribution of tipiracil hydrochloride</em></p><p><strong>&nbsp;</strong></p><p>Single-dose administration of Lonsurf (35 mg/m<sup>2</sup>/dose) increased the mean AUC<sub>0-last</sub> of trifluridine by 37-fold and C<sub>max</sub> by 22-fold with reduced variability compared to trifluridine alone (35 mg/m<sup>2</sup>/dose).</p><p>&nbsp;</p><p><em>Effect of food</em></p><p><em>&nbsp;</em></p><p>When Lonsurf at a single dose of 35 mg/m<sup>2 </sup>was administered to 14 patients with solid tumours after a standardised high-fat, high-calorie meal, trifluridine area under the concentration-time curve (AUC) did not change, but trifluridine C<sub>max</sub>, tipiracil hydrochloride C<sub>max</sub> and AUC decreased by approximately 40% compared to those in a fasting state.&nbsp; In clinical studies Lonsurf was administered within 1 hour after completion of the morning and evening meals (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The protein binding of trifluridine in human plasma was over 96% and trifluridine bound mainly to human serum albumin. Plasma protein binding of tipiracil hydrochloride was below 8%. Following a single dose of Lonsurf (35 mg/m<sup>2</sup>) in patients with advanced solid tumours, the apparent volume of distribution (Vd/F) for trifluridine and tipiracil hydrochloride was 21 L and 333 L, respectively.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Trifluridine was mainly eliminated by metabolism via TPase to form an inactive metabolite, FTY. The absorbed trifluridine was metabolised, and excreted into urine as FTY and trifluridine glucuronide isomers. Other minor metabolites, 5‑carboxyuracil &nbsp;and 5-carboxy-2&rsquo;-deoxyuridine, &nbsp;were detected, but those levels in plasma and urine were at low or trace levels.</p><p>&nbsp;</p><p>Tipiracil hydrochloride was not metabolised in human liver S9 or in cryopreserved human hepatocytes. Tipiracil hydrochloride was the major component and 6-hydroxymethyluracil was the major metabolite consistently in human plasma, urine, and faeces.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Following the multiple-dose administration of Lonsurf at the recommended dose and regimen, the mean elimination half-life (t<sub>1/2</sub>) for trifluridine on Day 1 of Cycle 1 and on Day 12 of Cycle 1 were 1.4 hours and 2.1 hours, respectively.&nbsp; The mean t<sub>1/2</sub> values for tipiracil hydrochloride on Day 1 of Cycle 1 and on Day 12 of Cycle 1 were 2.1 hours and 2.4 hours, respectively.</p><p><u>&nbsp;</u></p><p>Following a single dose of Lonsurf (35 mg/m<sup>2</sup>) in patients with advanced solid tumours, the oral clearance (CL/F) for trifluridine and tipiracil hydrochloride were 10.5 L/hr and 109 L/hr, respectively.<br />After single oral administration of Lonsurf with [<sup>14</sup>C]-trifluridine, the total cumulative excretion of radioactivity was 60% of the administered dose. The majority of recovered radioactivity was eliminated into urine (55% of the dose) within 24 hours, and the excretion into faeces and expired air was less than 3% for both. After single oral administration of Lonsurf with [<sup>14</sup>C]-tipiracil hydrochloride, recovered radioactivity was 77% of the dose, which consisted of 27% urinary excretion and 50% faecal excretion.<br />&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>In a dose finding study (15 to 35 mg/m<sup>2</sup> twice daily), the AUC from time 0 to 10 hours (AUC<sub>0-10</sub>) of trifluridine tended to increase more than expected based on the increase in dose; however, oral clearance (CL/F) and apparent volume of distribution (Vd/F) of trifluridine were generally constant at the dose range of 20 to 35mg/m<sup>2</sup>.&nbsp; As for the other exposure parameters of trifluridine and tipiracil hydrochloride, those appeared to be dose proportional.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special populations</u></p><p><em>&nbsp;</em></p><p><em>Age, gender and race</em></p><p><em>&nbsp;</em></p><p>Based on the population PK analysis, there is no clinically relevant effect of age, gender or race on the PK of trifluridine or tipiracil hydrochloride.</p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>Of the 533 patients in the RECOURSE study who received Lonsurf, 306 (57%) patients had normal renal function (CrCl&nbsp;&ge;&nbsp;90 mL/min), 178 (33%) patients had mild renal impairment (CrCl 60 to 89&nbsp;mL/min), and 47 (9%) had moderate renal impairment (CrCl 30 to 59&nbsp;mL/min), with data missing for 2 patients. Patients with severe renal impairment were not enrolled in the study.<em><u> </u></em></p><p><em><u>&nbsp;</u></em></p><p>Based on a population PK analysis, the exposure of Lonsurf in patients with mild renal impairment (CrCl&nbsp;=&nbsp;60 to 89 mL/min) was similar to those in patients with normal renal function (CrCl&nbsp;&ge;&nbsp;90&nbsp;mL/min). A higher exposure of Lonsurf was observed in moderate renal impairment (CrCl = 30 to 59&nbsp;mL/min). Estimated (CrCl) was a significant covariate for CL/F in both final models of trifluridine and tipiracil hydrochloride. The mean relative ratio of AUC in patients with mild (n=38) and moderate (n=16) renal impairment compared to patients with normal renal function (n=84) were 1.31 and 1.43 for trifluridine, respectively, and 1.34 and 1.65 for tipiracil hydrochloride, respectively.</p><p>&nbsp;</p><p>In a dedicated study the pharmacokinetics of trifluridine and tipiracil hydrochloride were evaluated in cancer patients with normal renal function (CrCl &ge;90 mL/min, N=12), mild renal impairment (CrCl =60 to 89 mL/min, N=12), moderate renal impairment (CrCl =30 to 59 mL/min, N=11), or severe renal impairment (CrCl =15 to 29 mL/min, N=8). Patients with severe renal impairment received an adjusted starting dose of 20 mg/m2 twice daily (reduced to 15 mg/m2 twice daily based on individual safety and tolerability). The effect of renal impairment after repeated administration was a 1.6- and 1.4-fold increase of trifluridine total exposure in patients with moderate and severe renal impairment, respectively, compared to patients with normal renal function; C<sub>max</sub> remained similar. The total exposure of tipiracil hydrochloride in patients with moderate and severe renal impairment after repeated administration was 2.3- and 4.1-fold higher, respectively, compared to patients with normal renal function; this being linked to a more decreased clearance with increasing renal impairment. The PK of trifluridine and tipiracil hydrochloride have not been studied in patients with end-stage renal disease (CrCl &lt; 15 mL/min or requiring dialysis) (see sections 4.2 and 4.4).</p><p><u>&nbsp;</u></p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>Based on the population PK analysis, liver function parameters including alkaline phosphatase (ALP, 36-2322 U/L), aspartate aminotransferase (AST, 11-197 U/L), alanine aminotransferase (ALT, 5-182 U/L) , and total bilirubin (0.17-3.20 mg/dL) were not significant covariates for PK parameters of either trifluridine or tipiracil hydrochloride. Serum albumin was found to significantly affect trifluridine clearance, with a negative correlation. For low albumin values ranging from 2.2 to 3.5 g/dL, the corresponding clearance values range from 4.2 to 3.1 L/h.</p><p>In a dedicated study the PK of trifluridine and tipiracil hydrochloride were evaluated in cancer patients with mild or moderate hepatic impairment (National Cancer Institute [NCI] Criteria Group B and C, respectively) and in patients with normal hepatic function. Based upon limited data with a considerable variability, no statistically significant differences were observed in the pharmacokinetics in patients with normal hepatic function versus patients with mild or moderate hepatic impairment. No correlation was seen for trifluridine nor tipiracil hydrochloride between PK parameters and AST or/and total blood bilirubin. Half-life time (t<sub>1/2</sub>) and the accumulation ratio of trifluridine and tipiracil hydrochloride were similar between the moderate, mild and normal hepatic function patients.</p><p>There is no need for a starting dose adjustment in patients with mild hepatic impairment (see section 4.2).</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Gastrectomy</em></p><p><em>&nbsp;</em></p><p>The influence of gastrectomy on PK parameters was not able to be examined in the population PK analysis because there were few patients who had undergone gastrectomy (1% of overall).</p><p>&nbsp;</p><p><em><u>In vitro</u></em><u> </u><u>interaction studies </u></p><p><u>&nbsp;</u></p><p>Trifluridine is a substrate of TPase, but is not metabolised by cytochrome P450 (CYP). Tipiracil hydrochloride is not metabolised in either human liver S9 or cryopreserved hepatocytes.</p><p>&nbsp;</p><p><em>In vitro</em> studies indicated that trifluridine, tipiracil hydrochloride and FTY (inactive metabolite of trifluridine) did not inhibit the CYP isoforms tested (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5). <em>In vitro</em> evaluation indicated that trifluridine, tipiracil hydrochloride and FTY had no inductive effect on human CYP1A2, CYP2B6 or CYP3A4/5. Thus trifluridine and tipiracil hydrochloride are not expected to cause or be subject to a significant medicinal product interaction mediated by CYP.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>In vitro</em> evaluation of trifluridine and tipiracil hydrochloride was conducted using human uptake and efflux transporters (trifluridine with MDR1, OATP1B1, OATP1B3 and BCRP; tipiracil hydrochloride with OAT1, OAT3, OCT2, MATE1, MDR1 and BCRP). Neither trifluridine nor tipiracil hydrochloride was an inhibitor of or substrate for human uptake and efflux transporters based on <em>in vitro </em>studies, except for OCT2 and MATE1. Tipiracil hydrochloride was an inhibitor of OCT2 and MATE1 <em>in vitro</em>, but at concentrations substantially higher than human plasma C<sub>max</sub> at steady state. Thus it is unlikely to cause an interaction with other medicinal products, at recommended doses, due to inhibition of OCT2 and MATE1. Transport of tipiracil hydrochloride by OCT2 and MATE1 might be affected when Lonsurf is administered concomitantly with inhibitors of OCT2 and MATE1.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>&nbsp;</p><p>The efficacy and safety of Lonsurf in metastatic colorectal cancer was compared between a high-exposure group (&gt;median) and a low-exposure group (&le;median) based on the median AUC value of trifluridine. OS appeared more favourable in the high AUC group compared to the low AUC group (median OS of 9.3 vs. 8.1 months, respectively). All AUC groups performed better than placebo throughout the follow-up period. The incidences of Grade &ge;3 neutropenia were higher in the high-trifluridine AUC group (47.8%) compared with the low-trifluridine AUC group (30.4%).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Repeat-dose toxicity</u></p><p>&nbsp;</p><p>Toxicology assessment of trifluridine/tipiracil hydrochloride was performed in rats, dogs and monkeys. The target organs identified were the lymphatic and haematopoietic systems and the gastrointestinal tract. All changes, i.e., leukopenia, anaemia, bone marrow hypoplasia, atrophic changes in the lymphatic and haematopoietic tissues and the gastrointestinal tract, were reversible within 9 weeks of drug withdrawal. Whitening, breakage, and malocclusion were observed in teeth of rats treated with trifluridine/tipiracil hydrochloride, which are considered rodent specific and not relevant for human.</p><p>&nbsp;</p><p><u>Carcinogenesis and mutagenesis</u></p><p><u>&nbsp;</u></p><p>No long term studies evaluating the carcinogenic potential of trifluridine/tipiracil hydrochloride in animals have been performed. Trifluridine was shown to be genotoxic in a reverse mutation test in bacteria, a chromosomal aberration test in mammal-cultured cells, and a micronucleus test in mice. Therefore, Lonsurf should be treated as a potential carcinogen.</p><p><u>&nbsp;</u></p><p><u>Reproductive toxicity</u></p><p><u>&nbsp;</u></p><p>Results of animal studies did not indicate an effect of trifluridine and tipiracil hydrochloride on male and female fertility in rats. The increases in the corpus luteum count and implanting embryo count observed in female rats at high doses were not considered adverse (see section 4.6). Lonsurf has been shown to cause embryo-foetal lethality and embryo-foetal toxicity in pregnant rats when given at dose levels lower than the clinical exposure. No peri/post-natal developmental toxicity studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p><u>&nbsp;</u></p><p>Lactose monohydrate</p><p>Starch, pregelatinised (maize)</p><p>Stearic acid</p><p>&nbsp;</p><p><u>Film coating</u></p><p><u>&nbsp;</u></p><p><em><u>Lonsurf 15 mg/6.14&nbsp;mg film-coated tablets</u></em></p><p>Hypromellose</p><p>Macrogol (8000)</p><p>Titanium dioxide (E171)</p><p>Magnesium stearate</p><p>&nbsp;</p><p><em><u>Lonsurf 20 mg/8.19&nbsp;mg film-coated tablets</u></em></p><p>Hypromellose</p><p>Macrogol (8000)</p><p>Titanium dioxide (E171)</p><p>Iron oxide red (E172)</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Printing ink</u></p><p><u>&nbsp;</u></p><p>Shellac</p><p>Iron oxide red (E172)</p><p>Iron oxide yellow (E172)</p><p>Titanium dioxide (E171)</p><p>Indigo carmine aluminium lake (E132)</p><p>Carnauba wax</p><p>Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
3 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Storage conditions: store below 30&deg;C. Store in the original carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/Aluminium blister with laminated desiccant (calcium oxide) containing 10 tablets.</p><p>&nbsp;</p><p>Each pack contains 20, 40 or 60 film-coated tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Handling: &bull; LONSURF is a cytotoxic drug. Considered as potential carcinogen. &bull; In healthcare settings, use designated area for medication storage and restrict access to only authorized personal &bull; To minimize the risk of dermal exposure, wear chemotherapy gloves and sleeve covers when handling LONSURF. This includes all handling activities in clinical settings, pharmacies, storerooms and home healthcare settings, including receiving, unpacking and, and storing within a facility. &bull; For transportation of intact tablet within the facility, wear single chemotherapy gloves and place in double bag or in a sealed container. &bull; The tablets should not be divided, broken or crushed. This might produce powder that can contaminate workplace surfaces. &bull; Caution should be observed in handling broken or crushed tablets; wear double chemotherapy gloves and place in double bag or in a sealed container. Avoid direct contact with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable. &bull; When manipulations are necessary such as compounding, crushing, cutting, or splitting; should be performed within a ventilated engineering enclosure and/ or augment the control of generated aerosols using supplementary controls such as glove bags or pill pouches that contain the hazardous drug during and after the crushing process. &bull; Wear double chemotherapy gloves, protective gown and sleeve covers. Add eye/face protection and respiratory protection [N95] if compounding is done outside of the ventilated engineering control. Hair and shoe covers should be worn. &bull; When clinically appropriate, add liquid or moist products to crushed hazardous drug product as soon as possible after crushing, to avoid the potential of subsequent aerosol dissemination.<br />&bull; For medication administration, wear single chemotherapy gloves with intact and coated tablets and double chemotherapy gloves with cut or crushed tablets. Add eye and face protection if there is the potential to contact vomit or if patient may resist or is pre-disposed to spitting out. &bull; Personnel who are pregnant should avoid exposure to crushed or broken coated tablets. Disposal: &bull; Wear double chemotherapy gloves and protective gown for any disposal or cleaning activity of medication contaminated waste. &bull; Avoid creating dusts. Place in sealed bags for disposal. Use caution when closing bags as pushing waste down may force hazardous drug dusts up into the user&rsquo;s face. &bull; For disposal of drugs and metabolites in body fluids, wear chemotherapy gloves and protective gown. Fold soft materials (sheets, hygiene care products) inward to prevent leakage and place in sealed bags. &bull; In case of spill, limit access to area, use wet wiping method (absorbent pads for liquid spills). Place in sealed bags for disposal. Disinfection, deactivation or decontamination agents may be necessary. &bull; Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Les Laboratoires Servier 
50 rue Carnot
92284 Suresnes Cedex
France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07.2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>